WO2017216297A1 - Dosage regimen - Google Patents
Dosage regimen Download PDFInfo
- Publication number
- WO2017216297A1 WO2017216297A1 PCT/EP2017/064682 EP2017064682W WO2017216297A1 WO 2017216297 A1 WO2017216297 A1 WO 2017216297A1 EP 2017064682 W EP2017064682 W EP 2017064682W WO 2017216297 A1 WO2017216297 A1 WO 2017216297A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxyamino
- oxopropyl
- amino
- cyclohexyl
- pyridin
- Prior art date
Links
- 238000011282 treatment Methods 0.000 claims abstract description 121
- AFDPFLDWOXXHQM-NRFANRHFSA-N cyclopentyl (2s)-2-cyclohexyl-2-[[6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl]methylamino]acetate Chemical compound C1=NC(CCC(=O)NO)=CC=C1CN[C@H](C(=O)OC1CCCC1)C1CCCCC1 AFDPFLDWOXXHQM-NRFANRHFSA-N 0.000 claims abstract description 115
- 150000003839 salts Chemical class 0.000 claims abstract description 86
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 83
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 81
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 77
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 52
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract description 50
- 241000282414 Homo sapiens Species 0.000 claims description 45
- 241001465754 Metazoa Species 0.000 claims description 27
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 abstract description 182
- 210000001616 monocyte Anatomy 0.000 description 192
- 235000002639 sodium chloride Nutrition 0.000 description 73
- 230000001363 autoimmune Effects 0.000 description 45
- 208000027866 inflammatory disease Diseases 0.000 description 34
- 206010003246 arthritis Diseases 0.000 description 28
- 239000003814 drug Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 230000007423 decrease Effects 0.000 description 19
- 210000002540 macrophage Anatomy 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 16
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- -1 salts Chemical compound 0.000 description 14
- 239000003435 antirheumatic agent Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 13
- 230000004968 inflammatory condition Effects 0.000 description 13
- 210000000265 leukocyte Anatomy 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 206010036030 Polyarthritis Diseases 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 208000030428 polyarticular arthritis Diseases 0.000 description 12
- 238000011084 recovery Methods 0.000 description 12
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 11
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 11
- 206010027906 Monocytosis Diseases 0.000 description 11
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 11
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 11
- 208000032839 leukemia Diseases 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 10
- 206010003658 Atrial Fibrillation Diseases 0.000 description 10
- 101000938676 Homo sapiens Liver carboxylesterase 1 Proteins 0.000 description 10
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 10
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 10
- 230000001174 ascending effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 10
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 238000004820 blood count Methods 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 210000002683 foot Anatomy 0.000 description 9
- 206010009900 Colitis ulcerative Diseases 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 description 8
- 210000004744 fore-foot Anatomy 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 102000003964 Histone deacetylase Human genes 0.000 description 7
- 108090000353 Histone deacetylase Proteins 0.000 description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 7
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 7
- 230000021736 acetylation Effects 0.000 description 7
- 238000006640 acetylation reaction Methods 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 208000003456 Juvenile Arthritis Diseases 0.000 description 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 206010043255 Tendonitis Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 235000008206 alpha-amino acids Nutrition 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 208000020947 enthesitis Diseases 0.000 description 6
- 208000013403 hyperactivity Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000001185 psoriatic effect Effects 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- 108010051152 Carboxylesterase Proteins 0.000 description 5
- 102000013392 Carboxylesterase Human genes 0.000 description 5
- 108090000371 Esterases Proteins 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940057948 magnesium stearate Drugs 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000004247 hand Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 3
- 229960000237 vorinostat Drugs 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 2
- 102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 201000002847 Cowden syndrome Diseases 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 239000004150 EU approved colour Substances 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 241000223997 Toxoplasma gondii Species 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 230000003367 anti-collagen effect Effects 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- GLNWREBYRLDPQP-MHZLTWQESA-N cyclopentyl (2s)-2-[[4-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-2-phenylacetate Chemical compound C1=CC(NC(=O)CCCCCCC(=O)NO)=CC=C1CN[C@@H](C=1C=CC=CC=1)C(=O)OC1CCCC1 GLNWREBYRLDPQP-MHZLTWQESA-N 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 150000002343 gold Chemical class 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000009491 slugging Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- LDJFZITUZWODKF-INIZCTEOSA-N (2s)-2-cyclohexyl-2-[[6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl]methylamino]acetic acid Chemical compound C1=NC(CCC(=O)NO)=CC=C1CN[C@H](C(O)=O)C1CCCCC1 LDJFZITUZWODKF-INIZCTEOSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 101150083327 CCR2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000012609 Cowden disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 244000207620 Euterpe oleracea Species 0.000 description 1
- 235000012601 Euterpe oleracea Nutrition 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000222732 Leishmania major Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 201000004253 NUT midline carcinoma Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010040628 Sialoadenitis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000035307 Vitreous adhesions Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000003650 acai Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 206010072959 birdshot chorioretinopathy Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000019748 bullous skin disease Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- VJNFFVZHSWYBGX-QFIPXVFZSA-N cyclopentyl (2s)-2-cyclohexyl-2-[[4-[3-(hydroxyamino)-3-oxopropyl]phenyl]methylamino]acetate Chemical compound C1=CC(CCC(=O)NO)=CC=C1CN[C@H](C(=O)OC1CCCC1)C1CCCCC1 VJNFFVZHSWYBGX-QFIPXVFZSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 210000002074 inflammatory monocyte Anatomy 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000002165 neuroretinitis Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 208000001050 sialadenitis Diseases 0.000 description 1
- 229950006094 sirukumab Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229950009112 tefinostat Drugs 0.000 description 1
- XTCIQWXJCPKWKC-IBGZPJMESA-N tert-butyl (2S)-2-cyclohexyl-2-[[6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl]methylamino]acetate Chemical compound C1(CCCCC1)[C@@H](C(=O)OC(C)(C)C)NCC=1C=NC(=CC=1)CCC(=O)NO XTCIQWXJCPKWKC-IBGZPJMESA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Definitions
- the present invention relates to (S) -cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis.
- the present invention relates to the use of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, in a novel dose and dosage regimen for the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis.
- the present invention is further directed to pharmaceutical compositions comprising said compound for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis by said novel dose or dosage regimen.
- the present invention further relates to methods of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis through administration of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, under a novel dose and dosage regimen.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- administration of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof
- Rheumatoid arthritis is a chronic inflammatory joint disease that affects approximately 1 % of the population in the industrialised world. I t affects approximately 3 times more women than men and onset is generally between 40 - 60 years of age. Rheumatoid arthritis is characterised by hyperplasia and inflammation of the synovial membrane, inflammation within the synovial fluid, and progressive destruction of the surrounding bone and cartilage. I t is a painful and debilitating condition , which can result in severe disability and ultimately affects a sufferer's ability to perform simple everyday tasks. Effects of rheumatoid arthritis vary between individuals, but the disease can progress very rapidly, causing swelling and damaging cartilage and bone around the joints. Any joint may be affected but most commonly the hands, feet and wrists.
- cytokines such as tumour necrosis factor alpha (TNFa) and interleukins, such as I L-1 , I L-6 and I L-8 (Li, 2013) .
- TNFa tumour necrosis factor alpha
- interleukins such as I L-1 , I L-6 and I L-8 (Li, 2013) .
- cytokines activate fibroblast-like synoviocytes which produce enzymes that damage the bones and cartilage.
- DMARDS Disease-modifying antirheumatic drugs
- Methotrexate MTX
- MTX Methotrexate
- combination treatment with biological DMARDS targeted to cytokines, B-cells or T-cells is the preferred treatment option (O'Dell, 2013) .
- a subset of these patients will still fail to achieve meaningful responses to treatment, or experience adverse events, and will continue to experience severely debilitating symptoms (Rubbert-Roth , 2009) .
- Histone deacetylase (HDAC) inhibitors have been shown to be active in various models of inflammation (Lin, 2007; Nishida, 2004; Joosten , 201 1 ; Gauben , 2008) .
- the role of HDAC inhibitors in cancer, neurological diseases and immune disorders has been reviewed ( Falkenberg KJ et al, Nat Rev Drug Discov, 13, 673-691 , (2014) .
- Falkenberg KJ et al Nat Rev Drug Discov, 13, 673-691 , (2014) .
- HDAC inhibitor The most studied HDAC inhibitor is the hydroxamic acid based compound vorinostat and this was approved in 2006 by the Food and Drug Association (FDA) for use in the treatment of cutaneous T-cell lymphoma (CTCL) .
- FDA Food and Drug Association
- CTCL cutaneous T-cell lymphoma
- HDAC inhibitors one of which is (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate.
- the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration twice a week, three times a week, or every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient.
- the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg twice a week, three times a week, or every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- FIG. 1 (a)— (f) Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers.
- Figure 1 shows the absolute monocyte counts over time obtained under the single ascending dose part of the study ( Part A) .
- FIG. 2 (a)-(e) Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers.
- Figure 2 shows the absolute monocyte counts over time obtained under the multiple ascending dose part of the study ( Part B)
- FIG. 3 Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)- 3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers.
- Figure 3 shows the concentration of acid in monocytes and non-monocytes obtained under the single ascending dose part of the study ( Part A)
- FIG. 4 Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)- 3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers.
- Figure 4 shows the concentration of acid in monocytes and non-monocytes on Day 1 and Day 7 obtained under the multiple ascending dose part of the study (Part B)
- FIG. 5 Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)- 3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers.
- Figure 5 shows the mean % change in acetylation of monocytes and non-monocytes obtained under the single ascending dose part of the study (Part A)
- FI G. 6 Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)- 3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers.
- Figure 6 shows thMean % Change in Acetylation of Monocytes and No n- Monocytes obtained under the multiple ascending dose part of the study (Part B)
- FI G. 7A/B Monocyte Count Profiling by K-PD Modelling. Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering three every other day doses of 20 and 40 mg of the compound of the invention .
- FI G. 7C Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering three every day doses of 20 and
- FI G. 7D Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering two doses of 20 and 40 mg of the compound of the invention , each one every three days (Q3D strategy) .
- DMARD Disease-Modifying Anti-Rheumatic Drugs
- DMARD includes among others hydroxycloroquine, sulfasalazine, methotrexate, leflunomide, azathioprine, D- penicillamine, gold salts (oral) , gold salts (intramuscular) , minocycline, cyclosporine including cyclosporine A and topical cyclosporine, and TNF-inhibitors (e.g.
- DMARDs herein are non-biological, i.e. classic DMARDs, including azathioprine, chloroquine, hydroxychloroquine, leflunomide, methotrexate and sulfasalazine. I n one embodiment, the DMARD is methotrexate.
- the phrase "every other day” means on alternate days and thus in the context of a drug administration regime, there is a day when the dose is not administered between each day when a dose is administered.
- An example of an "every other day” dosing regimen would be dosing on Day 1 , Day 3, Day 5, Day 7, with no dosing on the days inbetween (i.e. Day 2, Day 4, Day 6, Day 8 etc) .
- the phrase "twice a week” means that in a typical week consisting of seven days, there are two days when a subject is administered a dose of the compound of the invention and five days when the subject is not administered a dose of the compound of the invention.
- An example of a "twice a week” dosing regimen would be dosing on a Monday (e.g. Day 1 ) and Thursday (e.g. Day 4) .
- the phrase "three times a week” means that in a typical week consisting of seven days, there are three days when a subject is administered a dose of the compound of the invention and four days when the subject is not administered a dose of the compound of the invention.
- An example of a "three times a week" dosing regimen would be dosing on a Monday (e.g. Day 1 ) , Wednesday (e.g. Day 3) and Friday (e.g. Day 5) .
- pharmaceutically acceptable salt refers to a salt that retains the desired biological activity of the compound in question and exhibit minimal undesired toxicological effects.
- pharmaceutically-acceptable salts may be prepared in situ during the final isolation and purification of the compound, or by separately reacting the purified compound in its free acid or free base form with a suitable base or acid, respectively.
- compositions may be prepared during further processing of the free acid or base form, for example in situ during manufacture into a pharmaceutical composition.
- treatment refers to ameliorating or stabilising the specified condition, reducing or eliminating the symptoms of the condition, slowing or eliminating the progression of the condition, and preventing or delaying reoccurrence of the condition in a previously afflicted patient or subject.
- subject refers to an animal or human body.
- references herein to "compound of the invention” mean (S)-cyclopentyl 2-cyclohexyl-2-(((6- (3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, may be in crystalline or amorphous form , each of which are included within the scope of the present invention.
- the most thermodynamically stable crystalline form is of particular interest.
- Crystalline forms may be characterised and differentiated using a number of conventional analytical techniques, including, but not limited to, X-ray powder diffraction (XRPD) , infrared spectroscopy ( I R) , Raman spectroscopy, differential scanning calorimetry ( DSC) , thermogravimetric analysis (TGA) and solid-state nuclear magnetic resonance (ssNMR) .
- XRPD X-ray powder diffraction
- I R infrared spectroscopy
- Raman spectroscopy Raman spectroscopy
- DSC differential scanning calorimetry
- TGA thermogravimetric analysis
- ssNMR solid-state nuclear magnetic resonance
- I n one embodiment there is provided a crystalline solid state form of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate.
- I n a further embodiment there is provided an amorphous form of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl) amino)acetate.
- the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day. I n one embodiment, administration is every other day.
- the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration twice a week, three times a week, or every other day. I n one embodiment, administration is every other day.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient.
- the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg twice a week, three times a week, or every other day.
- administration is every other day.
- the present invention provides the use of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate is for administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate is an inhibitor of histone deacetylase (HDAC) enzymes and is disclosed in I nternational Patent Application Publication Number WO 2008/040934 as Example 62.
- HDAC histone deacetylase
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate is also known by the chemical name cyclopentyl (2S)-cyclohexyl[ ( ⁇ 6-[3- (hydroxyamino)-3-oxopropyl] pyridine-3-yl ⁇ methyl)amino] acetate.
- This compound comprises an alpha amino acid ester moiety that facilitates delivery of the compound into the cell.
- the molecule comprising the alpha amino acid ester is not charged and is freely transported through the cell wall. Once inside the cell, the alpha amino acid ester undergoes hydrolysis by intracellular carboxylesterases, particularly hCE-1 , to the corresponding carboxylic acid, (S)-2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetic acid, shown below. Being charged, the acid is not readily transported out of the cell and thus the intracellular concentration of the inhibitor increases, leading to an increase in cellular potency and duration of action .
- the acid which is disclosed in I nternational Patent Application Publication Number WO 2008/040934 as Example 103 has the following chemical structure:
- I n Part A from Cohort 2 ( 10 mg) onwards there was a decrease in the monocyte count observed at 4 hours and which showed a greater decrease at 24 hours post dosing.
- I n Part B in both cohorts (20 mg and 40 mg, each once daily) , rapid depletion of monocytes was observed which then plateaued around Day 2.
- Monocytes are a subset of circulating white blood cells and bloodstream monocytes are derived from the precursors in the bone marrow. Human monocytes are divided into subsets on the basis of surface CD14 and CD16 expression. The classical monocytes, CD14 ++ CD16 " monocytes, are the most prevalent subset in human blood. The CD16 + monocytes comprises two subsets, CD14 + CD16 ++ (non-classical) and CD14 + + CD16 + (intermediate) .
- Monocytes are part of the host anti-microbial defence system . Recruitment of monocytes has been shown to contribute to the control and clearance of multiple infective agents by trafficking to sites of infections where they secrete cytokines and chemokines, by differentiation into cells such as macrophages and dendritic cells and by direct killing of microbes (Serbina, N.V. , Jia, T. , Hohl, T. M. & Pamer, E. G. , Monocyte-mediated defense against microbial pathogens. Annu. Rev. Immunol. 26, 421 - 452 (2008)) .
- pathogens controlled by monocytes include, but are not limited to, bacteria such as Listeria monocytogenes (Pamer, E.G.
- Cryptococcus neoformans Traynor, T. R. , Kuziel, W. A. , Toews, G. B. & Huffnagle, G. B. CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection.
- J. Immunol. 1 64 , 2021 -2027 (2000) protozoan parasites such as Toxoplasma gondii ( Dunay, I . R. et al. Gr1 + inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate or a pharmaceutically acceptable salt thereof administered via a particular dosage regimen disclosed herein has the potential to provide an efficacious and safe treatment for a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis.
- the present invention provides (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration for at least 7 days in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration twice a week, three times a week, or every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate
- the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration twice a week, three times a week, or every other day for at least 7 days.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)a
- the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, wherein
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient.
- the present invention provides the use of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate is for administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
- the present invention provides a method of a chronic inflammatory and/or autoimmune disease, such as treating rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
- the present invention provides a method of a chronic inflammatory and/or autoimmune disease, such as treating rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day for at least 7 days.
- the present invention provides a method of a chronic inflammatory and/or autoimmune disease, such as treating rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S) -cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg every other day.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof is administered in an amount of about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, or 40 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof is administered every other day in an amount of about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, or 40 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof is administered twice a week in an amount of about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, or 40 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof is administered three times a week in an amount of about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, or 40 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof is administered in an amount of between 10 mg and 20 mg, between 20 mg and 30 mg, or between 30 mg and 40 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof is administered every other day in an amount between 10 mg and 20 mg, between 20 mg and 30 mg, or between 30 mg and 40 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof is administered twice a week in an amount between 10 mg and 20 mg, between 20 mg and 30 mg, between 30 mg and 40 mg, between 40 mg and 50 mg, or between 50 mg and 60 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof is administered three times a week in an amount between 10 mg and 20 mg, between 20 mg and 30 mg, or between 30 mg and 40 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof is administered every other day in an amount of about 40 mg.
- the present invention provides (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration every other day in an amount of about 40 mg.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises about 40 mg of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration every other day.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 40 mg, and a pharmaceutically acceptable excipient.
- the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 40 mg every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- I ncomplete or partial recovery of monocytes under a dosing strategy according to the present invention may enhance the therapeutic benefit in the treatment of a chronic inflammatory and/or autoimmune disease, in particular rheumatoid arthritis.
- Monocytes are central to the pathophysiology of rheumatoid arthritis. They are present in large numbers in inflamed joints and contribute to pathology through the release of cytokines and chemokines which drive inflammation and also via maturation into inflammatory macrophages and osteoclasts (C. A. Roberts et al, Frontiers in I mmunology, Vol. 6, Article 571 , (2015)) . Monocytes in the circulation of rheumatoid arthritis patients have also been shown to have an activated phenotype.
- administration of a compound of the invention according to a dosing regimen described herein in an amount of about 10 mg to about 40 mg permits recovery of circulating monocytes prior to administration of the next dose, wherein recovery is between 30% and 100% (e.g. greater than 30% , 40% , 50% , 60% , 70% , 80% , or 90% ) of the normal baseline level prior to treatment with a compound of the invention .
- administration of a compound of the invention every other day in an amount of about 20 mg to about 40 mg permits recovery of circulating monocytes prior to administration of the next dose, wherein recovery is between 50% and 80% (e.g. greater than 50% , 60% , or 70% ) of the normal baseline level prior to treatment with a compound of the invention.
- administration of a compound of the invention every other day in an amount of about 20 mg permits recovery of circulating monocytes prior to administration of the next dose, wherein recovery is between 60% and 80% (e.g. greater than 60% , or 70% ) of the normal baseline level pre-treatment with a compound of the invention.
- administration of a compound of the invention every other day in an amount of about 40 mg permits recovery of circulating monocytes prior to administration of the next dose, wherein recovery is between 50% and 70% (e.g. greater than 50% or 60%) of the normal baseline level prior to treatment with a compound of the invention.
- the dosage regimens described herein are for use in the treatment of inflammatory and/or autoimmune diseases in a human or animal subject. I n one embodiment, the dosage regimens described herein are for use in the treatment of chronic inflammatory and/or autoimmune diseases in a human or animal subject. I n one embodiment, the subject is a human.
- Autoimmune and/or inflammatory conditions include rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, pulmonary arterial hypertension (PAH) , multiple sclerosis, inflammatory bowel disease (Crohn's disease and ulcerative colitis) , asthma, chronic obstructive airways disease, pneumonitis, myocarditis, pericarditis, myositis, eczema, dermatitis (including atopic dermatitis) , alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis, hypercholesterolemia, atherosclerosis, Alzheimer's disease, depression, Sjogren's syndrome, sialoadenitis, central retinal vein occlusion, branched retinal vein occlusion , I rvine-Gass syndrome (post cataract and post-
- the chronic autoimmune and/or inflammatory condition is a systemic inflammatory disorder such as rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, multiple sclerosis or inflammatory bowel disease (Crohn's disease and ulcerative colitis) .
- a systemic inflammatory disorder such as rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, multiple sclerosis or inflammatory bowel disease (Crohn's disease and ulcerative colitis) .
- Viral infections include herpes simplex infections and reactivations, cold sores, herpes zoster infections and reactivations, chickenpox, shingles, human papilloma virus (HPV) , human immunodeficiency virus (HI V) , cervical neoplasia, adenovirus infections, including acute respiratory disease, poxvirus infections such as cowpox and smallpox and African swine fever virus.
- the viral infection is HI V infection.
- Cancers include haematological (such as leukaemia, lymphoma and multiple myeloma) , epithelial including lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and neurological tumours.
- haematological such as leukaemia, lymphoma and multiple myeloma
- epithelial including lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and neurological tumours.
- brain cancer gliomas
- glioblastomas Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease
- breast cancer inflammatory breast cancer, colorectal cancer, Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, ependymoma, medulloblastoma, colon cancer, head and neck cancer, kidney cancer, lung cancer, liver cancer, melanoma, squamous cell carcinoma, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma cancer, osteosarcoma, giant cell tumor of bone, thyroid cancer, lymphoblastic T-cell leukaemia, chronic myelogenous leukaemia, chronic lymphocytic leukaemia, hairy-cell leukaemia, acute lymphoblastic leukaemia, acute myelogenous leukaemia, chronic neutrophilic leukaemia, acute lymphoblastic T-cell leukaemia,
- the cancer is a leukaemia, for example a leukaemia selected from acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia and mixed lineage leukaemia (MLL) .
- a leukaemia selected from acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia and mixed lineage leukaemia (MLL) .
- Rheumatoid arthritis is an autoimmune disease characterised by chronic inflammation of synovial tissue, leading to destruction of the joint architecture. I t is a painful and debilitating condition, which can result in severe disability and ultimately affects a sufferer's ability to perform simple everyday tasks. Effects of rheumatoid arthritis vary between individuals, but the disease can progress very rapidly, causing swelling and damaging cartilage and bone around the joints. Any joint may be affected but most commonly the hands, feet and wrists.
- cytokines such as tumour necrosis factor alpha (TNFa) and interleukins, such as I L-1 , I L-6 and I L-8 (Li, 2013) .
- TNFa tumour necrosis factor alpha
- interleukins such as I L-1 , I L-6 and I L-8 (Li, 2013) .
- cytokines activate fibroblast-like synoviocytes which produce enzymes that damage the bones and cartilage.
- the dosage regimens described herein are for use in the treatment of moderate to severe rheumatoid arthritis.
- a commonly used method for classifiying disease activity in rheumatoid arthritis patients is Disease Activity Score of 28 joints (DAS 28).
- a DAS28 of ⁇ 3.2 is classified as inactive.
- a DAS28 of > 3.2 but ⁇ 5.1 is classified as moderate rheumatoid arthritis.
- a DAS28 of > 5.1 is classified as severe.
- the dosage regimens described herein are for use in the treatment of severe rheumatoid arthritis.
- the dosage regimens described herein are for use in the treatment of severe rheumatoid arthritis, i.e. wherein the patient has a DAS28 of > 5.1 .
- the dosage regimens described herein are for use in the treatment of subjects with severe rheumatoid arthritis despite treatment with existing therapies, such as conventional and biological disease modifying anti-rheumatic drugs (DMARDs) .
- I n a separate and further aspect of the invention there is provided the compound of the invention for use in the treatment of autoimmune and/or inflammatory conditions.
- I n a further aspect of the present invention there is provided a method of treatment of an autoimmune and/or inflammatory condition , which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention .
- the present invention is directed to the use of a compound of the invention in the manufacture of a medicament for use in the treatment of an autoimmune and/or inflammatory condition.
- the compound of the invention for use in the treatment of arthritis, for example rheumatoid arthritis (e.g. severe rheumatoid arthritis) .
- arthritis for example rheumatoid arthritis (e.g. severe rheumatoid arthritis) .
- a method of treatment of arthritis for example rheumatoid arthritis (e.g. severe rheumatoid arthritis) , which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention.
- the present invention is directed to the use of a compound of the invention in the manufacture of a medicament for use in the treatment of arthritis (for example rheumatoid arthritis (e.g. severe rheumatoid arthritis)) .
- data disclosed herein demonstrate that the compound of the invention possesses monocyte-depletion activity (e.g. depletion of circulating blood monocytes) separate from an HDAC inhibitory effect, and thus may be used to effectively deplete circulating blood monocytes.
- monocyte-depletion activity e.g. depletion of circulating blood monocytes
- This property may be exploited in the treatment or prevention of diseases (e.g. autoimmune and/or inflammatory diseases, and cancers) where monocytes are known to play an important role in the development and progression of the disease.
- diseases e.g. autoimmune and/or inflammatory diseases, and cancers
- an HDAC inhibitor comprising a carboxylesterase sensitive motif for use in the treatment of prevention of an autoimmune and/or inflammatory condition , wherein the HDAC inhibitor is administered at a dose which results in depletion of circulating blood monocytes.
- HDAC inhibitor comprising a carboxylesterase sensitive motif refers to a covalent conjugate of an HDAC inhibitor and an alpha amino acid ester, wherein the ester group of the alpha amino acid ester is hydrolysable by one or more intracellular carboxylesterases to the corresponding carboxylic acid.
- Covalent conjugates of an HDAC inhibitor and an alpha amino acid ester are disclosed in, for example, WO2006/ 1 17567, WO2006/ 1 17549, WO2008/040934, WO2008/053131 , WO2009/ 106848, WO2006/ 1 17548, WO2008/053131 , WO2008/040934, WO2010/097586, WO2012/025701 , and each of these covalent conjugates (e.g. tefinostat, which is also known as CHR-2845, or a pharmaceutically acceptable salt thereof) are incorporated herein by reference and may be utilised in the methods of treatment/medical uses described herein below.
- tefinostat which is also known as CHR-2845, or a pharmaceutically acceptable salt thereof
- I n one aspect of the invention there is provided the compound of the invention for use in the treatment or prevention of an autoimmune and/or inflammatory disease, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes.
- a method of treatment or prevention of an autoimmune and/or inflammatory condition which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention , wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes.
- the present invention is directed to the use of a compound of the invention in the manufacture of a medicament for use in the treatment or prevention of an autoimmune and/or inflammatory condition, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes.
- depletion of circulating blood monocytes may be prolonged depletion, i.e. for at least the duration of the treatment period with the compound of the invention .
- administration of a compound of the invention results in depletion of circulating monocytes to between 10% and 90% (e.g.
- administration of a compound of the invention results in depletion of circulating monocytes to between 10% and 30% of the normal baseline level prior to treatment with a compound of the invention .
- I n a further aspect of the invention there is provided a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject comprising administration to the subject in need thereof a therapeutically effective amount of an HDAC inhibitor comprising a carboxylesterase sensitive motif.
- a method of modulating monocytes e.g. circulating blood monocytes
- macrophages and/or dendritic cells in a subject comprising administration to the subject in need thereof a therapeutically effective amount of a compound of the invention.
- the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer.
- the present invention provides a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject comprising administration to the subject in need thereof a therapeutically effective amount of a compound of the invention, wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease, and wherein the method decreases, reduces, suppresses, limits, or inhibits an undesired or aberrant immune or inflammatory component of an autoimmune and/or inflammatory disease.
- monocytes e.g. circulating blood monocytes
- macrophages and/or dendritic cells e.g. circulating blood monocytes
- dendritic cells e.g. circulating blood monocytes
- the method decreases, reduces, suppresses, limits, or inhibits an undesired or aberrant immune or inflammatory component of an autoimmune and/or inflammatory disease.
- I n a further aspect of the invention there is provided a method of modulating monocytes (e.g. circulating blood monocytes) in a subject comprising administration to the subject in need thereof a therapeutically effective amount of an HDAC inhibitor comprising a carboxylesterase sensitive motif.
- a method of modulating monocytes e.g. circulating blood monocytes
- the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer.
- the present invention provides a method of modulating monocytes (e.g.
- circulating blood monocytes in a subject comprising administration to the subject in need thereof a therapeutically effective amount of a compound of the invention , wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease, and wherein the method decreases, reduces, suppresses, limits, or inhibits an undesired or aberrant immune or inflammatory component of an autoimmune and/or inflammatory disease.
- the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject.
- monocytes e.g. circulating blood monocytes
- macrophages and/or dendritic cells in a subject.
- the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer.
- the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes)and/or macrophages and/or dendritic cells in a subject who has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer.
- the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject, wherein the method decreases, reduces, suppresses, limits, or inhibits an undesired or aberrant immune or inflammatory component of an autoimmune and/or inflammatory disease.
- monocytes e.g. circulating blood monocytes
- macrophages and/or dendritic cells e.g. circulating blood monocytes
- dendritic cells e.g. circulating blood monocytes
- the subject whose monocytes and/or macrophages and/or dendritic cells will be modulated following administration of a compound of the invention is at risk of developing or has been diagnosed with an autoimmune and/or inflammatory condition as set forth herein.
- the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) in a subject.
- the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer.
- the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) in a subject who has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer.
- the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g.
- the method decreases, reduces, suppresses, limits, or inhibits an undesired or aberrant immune or inflammatory component of an autoimmune and/or inflammatory disease.
- the subject whose monocytes will be modulated following administration of a compound of the invention is at risk of developing or has been diagnosed with an autoimmune and/or inflammatory condition as set forth herein.
- the present invention is further directed to a method for attenuating monocyte hyperactivity in a subject (e.g. a human subject) comprising administering to the subject in need thereof a therapeutically effective amount of an HDAC inhibitor comprising a carboxylesterase sensitive motif, wherein monocyte hyperactivity is attenuated.
- the present invention is further directed to a method for attenuating monocyte hyperactivity in a subject (e.g. a human subject) comprising administering to the subject in need thereof a therapeutically effective amount of a compound of the invention, wherein monocyte hyperactivity is attenuated.
- the present invention provides a compound of the invention for use in attenuating monocyte hyperactivity in a subject (e.g. a human subject) .
- the subject with monocyte hyperactivity is at risk of developing or has been diagnosed with an autoimmune and/or inflammatory disease as set forth herein .
- the subject is a human subject.
- the term "at risk” refers to those subjects who have a high probability of developing a disease, determined by, for example, genetic predisposition (i.e. family history and/or detection of one or more genetic polymorphisms or mutations) , biomarker analysis and/or imaging.
- the term "modulating, depleting or attenuating” refers to decreasing or reducing (e.g. the amount of circulating blood monocytes) either permanently (e.g. apoptosis) or transiently (e.g. margination or retention in tissues and/or decreased production) .
- Monocyte levels may be decreased or reduced to between 10% and 90% (e.g. less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level prior to treatment with a compound of the invention .
- the normal baseline level may be determined by performing a Full Blood Count ( FBC) test.
- FBC Full Blood Count
- the monocyte level may be decreased or reduced to between 10% and 90% (e.g. between 10% and 30% , or less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal monocyte range of 0.2 - 1 .5 x 10 9 cells/L.
- Depletion or reduction of monocytes refers to depletion or reduction of one or more of the three recognised subsets of monocytes: classical, non-classical and intermediate.
- all subsets of monocytes are depleted/reduced/modulated/ attenuated.
- autoimmune and/or inflammatory diseases that may be treated or prevented with a compound of the invention, via depletion/modulation/reduction/attenuation of monocytes (e.g. circulating blood monocytes) include inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , and primary biliary cirrhosis ( PBC) .
- monocytes e.g. circulating blood monocytes
- inflammatory bowel disease Crohn's disease and ulcerative colitis
- NASH non-alcoholic steato hepatitis
- PBC primary biliary cirrhosis
- I n a further embodiment, autoimmune and/or inflammatory diseases that may be treated with a compound of the invention, via depletion/modulation/reduction/attenuation of monocytes (e.g.
- circulating blood monocytes include psoriatic arthritis ( PsA) , ankylosing spondylitis (AS) , atrial fibrillation, and juvenile idiopathic arthritis (e.g. systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated) .
- PsA psoriatic arthritis
- AS ankylosing spondylitis
- atrial fibrillation e.g. systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated
- juvenile idiopathic arthritis e.g. systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic, enthes
- the autoimmune and/or inflammatory disease that may be treated with a compound of the invention, via depletion/modulation/reduction/attenuation of monocytes is multiple sclerosis.
- the autoimmune and/or inflammatory disease that may be treated with a compound of the invention , via depletion/modulation/reduction/attenuation of monocytes is atherosclerosis.
- the compound of the invention, via depletion/modulation/reduction/attenuation of monocytes e.g. circulating blood monocytes
- the capability of the compound of the invention to deplete monocytes may be useful for the treatment of monocytosis.
- Monocytosis which occurs during chronic inflammation , is an increase in the number of monocytes circulating in the blood.
- a monocyte count above 950/ ⁇ _ is regarded as monocytosis.
- a compound of the invention for use in the treatment of monocytosis there is provided a compound of the invention for use in the treatment of monocytosis wherein the compound of the invention results in the depletion of monocytes (e.g. circulating blood monocytes) .
- I n a further aspect of the present invention there is provided a method of treatment of monocytosis, which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention .
- a method of treatment of monocytosis which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes.
- the present invention is directed to the use of a compound of the invention in the manufacture of a medicament for use in the treatment of monocytosis.
- the present invention is directed to the use of a compound of the invention in the manufacture of a medicament for use in the treatment of monocytosis, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes.
- a subject e.g. a human subject diagnosed with monocytosis may have an autoimmune and/or inflammatory condition.
- Embodiment 1 The compound of the invention for use in the treatment or prevention of an autoimmune and/or inflammatory disease and/or cancer in a subject, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes and/or macrophages and/or dendritic cells.
- Embodiment 2 The compound for use according to Embodiment 1 , wherein depletion of circulating blood monocytes may be prolonged depletion, i.e. for at least the duration of the treatment period with the compound of the invention .
- Embodiment 3 The compound for use according to Embodiment 1 or 2, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 90% (e.g. between 10% and 30% , or less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with a compound of the invention .
- 10% and 90% e.g. between 10% and 30% , or less than 20% , 30% , 40% , 50% , 60% , 70% , or 80%
- the normal baseline level optionally determined by performing a Full Blood Count
- Embodiment 4 The compound for use according to Embodiment 3, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 30% of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention.
- Embodiment 5 The compound for use according to any of Embodiments 1 to 4, wherein the autoimmune and/or inflammatory disease is selected from the group consisting of : inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , primary biliary cirrhosis ( PBC) , psoriatic arthritis ( PsA) , ankylosing spondylitis (AS) , atrial fibrillation, juvenile idiopathic arthritis (e.g.
- inflammatory bowel disease Crohn's disease and ulcerative colitis
- NASH non-alcoholic steato hepatitis
- PBC primary biliary cirrhosis
- PsA psoriatic arthritis
- AS ankylosing spondylitis
- atrial fibrillation juvenile idiopathic arthritis
- oligoarthritis systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated) , rheumatoid arthritis, multiple sclerosis and atherosclerosis.
- Embodiment 6 The compound for use according to any of Embodiments 1 to 5, wherein the subject is a human subject.
- Embodiment 7 The compound for use according to any of Embodiments 1 to 6, wherein the compound of the invention is (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate.
- Embodiment 8 The compound for use according to any of Embodiments 1 to 7, wherein the use is for the treatment of an autoimmune and/or inflammatory disease.
- Embodiment 9 The compound for use according to any of Embodiments 1 to 8, wherein the compound of the invention results in depletion of one or more subsets (classical, non-classical and intermediate) of circulating blood monocytes.
- Embodiment 10 The compound for use according to any of Embodiments 1 to 9, wherein the compound of the invention results in depletion of all subsets (classical, non-classical and intermediate) of circulating blood monocytes.
- Embodiment 1 1 The compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject.
- monocytes e.g. circulating blood monocytes
- macrophages e.g. circulating blood monocytes
- dendritic cells e.g. circulating blood monocytes
- Embodiment 12 The compound for use according to Embodiment 1 1 , wherein the monocyte (e.g. circulating blood monocytes) level is decreased or reduced to between 10% and 90% (e.g. less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention.
- the monocyte e.g. circulating blood monocytes
- 90% e.g. less than 20% , 30% , 40% , 50% , 60% , 70% , or 80%
- Embodiment 13 The compound for use according to Embodiment 12, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 30% of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention .
- Embodiment 14 The compound for use according to any of Embodiments 1 1 to 13, wherein the subject is a human subject.
- Embodiment 15 The compound for use according to any of Embodiments 1 1 to 14, wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer.
- Embodiment 16 The compound for use according to any of Embodiments 1 1 to 15, wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease and the compound of the invention is for the treatment of said disease.
- Embodiment 17 The compound for use according to Embodiment 15 or 16, wherein the autoimmune and/or inflammatory disease is selected from the group consisting of : inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , primary biliary cirrhosis (PBC) , psoriatic arthritis (PsA) , ankylosing spondylitis (AS) , atrial fibrillation , juvenile idiopathic arthritis (e.g.
- oligoarthritis systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated) , rheumatoid arthritis, multiple sclerosis and atherosclerosis.
- Embodiment 18 The compound for use according to any of Embodiments 1 1 to 17, wherein the compound of the invention is (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate.
- Embodiment 19 The compound for use according to any of Embodiments 1 1 to 18, wherein the compound of the invention results in modulation of one or more subsets (classical, non-classical and intermediate) of circulating blood monocytes.
- Embodiment 20 The compound for use according to any of Embodiments 1 1 to 19, wherein the compound of the invention results in depletion of all subsets (classical, non-classical and intermediate) of circulating blood monocytes.
- Embodiment 21 A method of treatment or prevention of an autoimmune and/or inflammatory condition and/or cancer, which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes.
- Embodiment 22 A method of treatment according to Embodiment 21 , wherein depletion of circulating blood monocytes may be prolonged depletion, i.e. for at least the duration of the treatment period with the compound of the invention .
- Embodiment 23 A method of treatment according to Embodiment 21 or 22, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 90% (e.g. between 10% and 30% , or less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with a compound of the invention .
- 10% and 90% e.g. between 10% and 30% , or less than 20% , 30% , 40% , 50% , 60% , 70% , or 80%
- the normal baseline level optionally determined by performing a Full Blood Count
- Embodiment 24 A method of treatment according to Embodiment 23, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 30% of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention.
- Embodiment 25 A method of treatment according to any of Embodiments 21 to 24, wherein the autoimmune and/or inflammatory disease is selected from the group consisting of : inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , primary biliary cirrhosis ( PBC) , psoriatic arthritis ( PsA) , ankylosing spondylitis (AS) , atrial fibrillation, juvenile idiopathic arthritis (e.g.
- oligoarthritis systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated) , rheumatoid arthritis, multiple sclerosis and atherosclerosis.
- Embodiment 26 A method of treatment according to any of Embodiments 21 to 25, wherein the subject is a human subject.
- Embodiment 27 A method of treatment according to any of Embodiments 21 to 26, wherein the compound of the invention is (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate.
- Embodiment 28 A method of treatment according to any of Embodiments 21 to 27, wherein the method of treatment is of an autoimmune and/or inflammatory disease.
- Embodiment 29 A method of treatment according to any of Embodiments 21 to 28, wherein the compound of the invention results in depletion of one or more subsets (classical, non-classical and intermediate) of circulating blood monocytes.
- Embodiment 30 A method of treatment according to any of Embodiments 21 to 29, wherein the compound of the invention results in depletion of all subsets (classical, non-classical and intermediate) of circulating blood monocytes.
- Embodiment 31 A method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject comprising administration to the subject in need thereof a therapeutically effective amount of a compound of the invention.
- monocytes e.g. circulating blood monocytes
- macrophages and/or dendritic cells e.g. circulating blood monocytes
- dendritic cells e.g. circulating blood monocytes
- Embodiment 32 A method of modulating according to Embodiment 31 , wherein the monocyte (e.g. circulating blood monocytes) level in a subject is decreased or reduced to between 10% and 90% (e.g. less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention.
- the monocyte e.g. circulating blood monocytes
- 90% e.g. less than 20% , 30% , 40% , 50% , 60% , 70% , or 80%
- Embodiment 33 A method of modulating according to Embodiment 32, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 30% of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention .
- Embodiment 34 A method of modulating according to any of Embodiments 31 to 33, wherein the subject is a human subject.
- Embodiment 35 A method of modulating according to any of Embodiments 31 to 34, wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer.
- Embodiment 36 A method of modulating according to any of Embodiments 31 to 35, wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease and the compound of the invention is for the treatment of said disease.
- Embodiment 37 A method of modulating according to Embodiment 35 or 36, wherein the autoimmune and/or inflammatory disease is selected from the group consisting of : inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , primary biliary cirrhosis ( PBC) , psoriatic arthritis ( PsA) , ankylosing spondylitis (AS) , atrial fibrillation, juvenile idiopathic arthritis (e.g. systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis,
- the autoimmune and/or inflammatory disease is selected from the group consisting of : inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , primary biliary cirrhosis ( PBC) , psoriatic arthritis ( PsA) , anky
- RF-positive polyarthritis psoriatic, enthesitis-related, and undifferentiated
- rheumatoid arthritis multiple sclerosis and atherosclerosis.
- Embodiment 38 A method of modulating according to any of Embodiments 31 to 37, wherein the compound of the invention is (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate.
- Embodiment 39 A method of modulating according to any of Embodiments 31 to 38, wherein the compound of the invention results in modulation of one or more subsets (classical, non-classical and intermediate) of circulating blood monocytes.
- Embodiment 40 A method of modulating according to any of Embodiments 31 to 39, wherein the compound of the invention results in depletion of all subsets (classical, non-classical and intermediate) of circulating blood monocytes.
- the pharmaceutical composition comprising a compound of the invention further comprises a pharmaceutically acceptable excipient.
- the pharmaceutical composition comprises a compound of the invention and one or more pharmaceutically acceptable excipient(s) .
- a pharmaceutical composition comprising (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient.
- a pharmaceutical composition comprising (S) -cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin- 3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient.
- the pharmaceutical composition comprises (S)-cyclopentyl 2-cyclohexyl- 2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 40 mg.
- any excipients utilised must be pharmaceutically acceptable and be compatible with the other components (other excipients and the active ingredient) of the composition.
- a process for the preparation of a pharmaceutical composition including admixing (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, with a pharmaceutically acceptable excipient.
- compositions for use in the treatment of rheumatoid arthritis according to the present invention may be administered orally. Such compositions may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the excipient(s) .
- Pharmaceutical compositions adapted for oral administration may be presented as discrete units such as tablets or capsules, powders or granules, solutions or suspensions in aqueous or non-aqueous liquids, edible foams or whips, or oil-in-water liquid emulsions or water-in-oil liquid emulsions. I n one embodiment, the pharmaceutical composition is adapted for oral administration.
- the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by oral administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by oral administration every other day in an amount of about 10 mg to about 40 mg.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate is administered orally in an amount of about 40 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate is administered orally in an amount of about 20 mg.
- the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for oral administration twice a week, three times a week, or every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)a
- the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for oral administration every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the pharmaceutical composition comprises about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition comprises about 20 mg of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for oral administration.
- the pharmaceutical composition comprises about 40 mg of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition comprises about 20 mg of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof.
- the present invention provides the use of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate is for oral administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
- the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises orally administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6- (3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises orally administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6- (3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg every other day.
- a chronic inflammatory and/or autoimmune disease such as rheumatoid arthritis
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate is administered orally in an amount of about 40 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate is administered orally in an amount of about 20 mg.
- the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises orally administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6- (3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day, wherein (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, is in the form of a pharmaceutical composition.
- the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises orally administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6- (3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg every other day, wherein (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, is in the form of a pharmaceutical composition .
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate is administered orally in an amount of about 40 mg.
- (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate is administered orally in an amount of about 20 mg.
- compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
- Preferred unit dosage compositions are those containing the dose for an entire day or sub-dose, or an appropriate fraction thereof, of an active ingredient.
- Unit doses that contain a sub-dose of the recommended dose for a day may therefore be administered more than once in order to make up the total dose for a day.
- a dose on a particular day is 40 mg, this may be contained in one unit or in multiple units (e.g. 4 units each comprising 10 mg of active ingredient) , wherein a unit may for example be a tablet or capsule.
- the pharmaceutical composition is in unit dosage form .
- the unit dosage form is a tablet or a capsule.
- Powders suitable for incorporating into tablets or capsules may be prepared by reducing a compound of the invention to a suitable fine size (e.g. by micronisation) and mixing with a similarly prepared pharmaceutical excipient such as an edible carbohydrate, for example, starch or mannitol.
- a pharmaceutical excipient such as an edible carbohydrate, for example, starch or mannitol.
- Flavouring, preservative, dispersing and colouring agents for example, may also be present.
- Capsules may be made by preparing a powder mixture and filling formed gelatin sheaths.
- Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate, sodium stearate, sodium oleate, sodium benzoate, sodium acetate, sodium chloride and the like, or solid polyethylene glycol can be added to the powder mixture before the filling operation .
- a diluent such as microcrystalline cellulose can also be added.
- a disintegrating or solubilising agent such as agar- agar, starch, methyl cellulose, bentonite, xanthan gum , calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
- Suitable binders include starch (e.g. pregelatinised starch) , gelatin , natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
- each capsule comprises a compound of the invention, pregelatinised starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate.
- each capsule comprises 10 to 40 mg of a compound of the invention , pregelatinised starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate.
- each capsule comprises 20 mg of a compound of the invention, pregelatinised starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate.
- each capsule comprises 40 mg of a compound of the invention, pregelatinised starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate.
- Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets.
- a powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin , a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate.
- a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone
- a solution retardant such as paraffin
- a resorption accelerator such as a quaternary salt
- an absorption agent such as bentonite, kaolin or dicalcium phosphate.
- the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
- a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
- the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
- the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
- the lubricated mixture is then compressed into tablets.
- a compound of the invention can also be combined with a free flowing inert excipient and compressed into tablets directly without going through the granulating or slugging steps.
- a clear or opaque protective coating consisting of a sealing coat of shellac, a coating
- a tablet formulation may comprise a compound of the invention and microcrystalline cellulose, mannitol, croscarmellose sodium , hypromellose and magnesium stearate.
- Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
- Syrups can be prepared by dissolving the compound in a suitably flavoured aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
- Suspensions can be formulated by dispersing the compound in a non-toxic vehicle.
- Solubilisers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavour additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
- dosage unit compositions for oral administration can be microencapsulated.
- (S) -cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof for use according to the present invention may be administered in combination with one or more (e.g. two) other therapeutic agents that treat a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis.
- the additional therapeutic agent(s) include, for example, immunosuppressive agents, non-steroidal anti-inflammatory drugs (NSAI Ds) , disease modifying anti-rheumatic drugs (DMARDs) , such as methotrexate (MTX) , anti-B-cell surface marker antibodies, such as anti-CD20 antibodies (e.g. rituximab) , TNF-alpha-inhibitors (e.g. infliximab, adalimumab, certolizumab pegol, golimumab, or etanercept) , anti-I L-6 antibodies (e.g.
- anti-GM-CSF antibodies e.g. an antibody having amino acid sequence and DNA sequence as provided in Figure 1 of WO 2014/044768
- corticosteroids e.g. prednisone
- the additional therapeutic agent(s) is selected from the group consisting of non- biological DMARDs, NSAI DS, and corticosteroids.
- Additional therapeutic agents may be administered via the same or a different administration route as (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin- 3-yl) methyl)amino)acetate according to the present invention. Furthermore, they may be
- I f additional therapeutic agents are utilised, in one embodiment, the combined action of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate and the additional therapeutic agent(s) is greater than the sum or each acting separately.
- the combination of two or more therapeutic agents may, thus, provide a synergistic effect.
- Combination therapy with one or more additional therapeutic agents includes coadministration (simultaneous administration) and sequential or consecutive administration .
- Agents intended for use in combination may be formulated in separate compositions or, if the same dosage regimen can be used for all agents, a single pharmaceutical composition .
- the other therapeutic agent(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or as solvates, for example hydrates, to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic agent.
- the therapeutic agents may be used in optically pure form .
- Capsule Composition 1
- Capsules are white, opaque, hard gelatine capsules for oral administration.
- the capsules may be packed into high-density polyethylene (HDPE) bottles with child resistant closures and also may include a dessicant.
- HDPE high-density polyethylene
- the compound was found to be well tolerated ; however, a decision was made to not complete the final planned cohort at 60 mg in order to investigate the emergence of an unexpected pharmacodynamic observation : marked depletion of circulating monocytes.
- I n Part A from Cohort 2 (10 mg) onwards there was a decrease in the monocyte count observed at 4 hours and which showed a greater decrease at 24 hours post dosing.
- I n the post-dose sample collected at post-study physical examination (performed between 4 to 7 days after the last study treatment) the decrease in monocytes had reversed (see Figure 1 ) .
- I n Part B in both cohorts (20 mg and 40 mg) , rapid depletion in monocytes was seen which then plateaued around Day 2.
- I n the post-dose sample collected at post-study physical examination (performed between 4 to 7 days after the last study treatment) the monocyte count had returned to baseline (see Figure 2) .
- the concentration of the acid hydrolysis product in monocytes and non-monocyte cell populations was determined as part of the study.
- non-monocytes tended to occur at approximately 1 hour post-dose across all treatment groups (see Figure 3) .
- the mean concentration of the acid in monocytes (negatively selected from PBMCs) and in non-monocytes (remaining PBMCs) tended to increase with dose at all timepoints.
- concentrations of the acid tended to be higher in monocytes than in non-monocytes and remained detectable 12 hours post dose, well beyond plasma concentrations. Concentration above I C90 was maintained for up to 1 .8 hours at 20 mg and up to 7.6 hours at 40 mg after one single dose.
- the peak mean concentration of acid in monocytes and non-monocytes tended to occur at 1 hour post-dose across both active treatment groups on Day 1 and on Day 7 (see Figure 4) .
- the mean concentration of acid in monocytes and non-monocytes tended to increase with dose at 1 and 4 hours post-dose at Day 1 , but not at Day 7.
- Concentrations of the acid tended to be much higher in monocytes than in non-monocytes from 1 hour to 12 hours post-dose.
- Pre-dose levels of the acid on Day 7 in monocytes were similar to levels on Day 1 , 12 hours post-dose.
- Cytokines levels were measured in fasted state. In general, for all cytokines (TNFa, IL-6, I L- 10, I FN- ⁇ and IL- ⁇ ) some degree of inhibition of LPS-induced production was observed.
- I n Part A mean percentage levels of LPS-induced TNFa and LPS-induced I L-6 were below 50% of baseline levels in Cohort 3 (20 mg, fasted) , Cohort 4 (40 mg, fasted) , Cohort 5 (60 mg) and Cohort 6 (50 mg) , and these levels remained below 50% up to 12 hours post-dose. Levels of LPS- induced I L-10 were also below 50% of baseline levels in Cohort 2 (10 mg) , Cohort 3 (20 mg, fasted) , Cohort 4 (40 mg, fasted) , Cohort 5 (60 mg) and Cohort 6 (50 mg) with levels remaining below 50% of baseline levels in Cohorts 4, 5 and 6 up to 12 hours post-dose. Mean percentage levels of LPS-induced I L- ⁇ of Cohort 4 (40 mg, fasted) , Cohort 5 (60 mg) and Cohort 6 (50 mg) , remained below 50% of baseline levels up to 12 hours post-dose.
- I n Part B mean percentage levels of LPS-induced TNFa, IL-6, I L-10, I FN- ⁇ and IL- ⁇ were less than 50% from baseline on Day 1 , and remained below 50% of baseline levels at 12 hours post-dose on Day 7 for both cohorts. For all cytokine levels across the 2 treatment groups, there was a difference between placebo and active treatments.
- mice generated with the human hCE-1 gene under the control of the human CD68 promoter to drive expression in monocytes and macrophages [Gough, 2001 ] .
- these transgenic mice were also crossed with an esterase-deficient ( Es1 e) mice to generate hCE-1 / Es1 e strain.
- the compound at 10 mg/kg/day by intraperitoneal ( I P) injection was selected as a standard dose and 6 hours was selected as the standard timepoint across all studies.
- This study was designed to compare the effects of a single intaperitoneal dose of two targeted HDAC inhibitors ((S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate and (S)-cyclopentyl 2-cyclohexyl-2-((4-(3-(hydroxyamino)-3- oxopropyl)benzyl)amino)acetate) and the non-targeted HDAC inhibitor SAHA (vorinostat) on leukocyte populations in the blood of male hCE1 / Es1 e mice at 6h post dose.
- SAHA vorinostat
- Leukocyte populations were assessed by flow cytometry phenotyping and the study was designed to determine the effects of the non-hydrolysable t-butyl control molecule dosed at 10 mg/kg on circulating leukocytes, and to evaluate the effects of 3 mg/kg and 10 mg/kg (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)- 3-oxopropyl)pyridin-3-yl)methyl) amino)acetate on circulating leukocytes compared to vehicle-treated animals.
- ACAI A murine Anti- Collagen Antibody I nduced Arthritis
- I P intaperitoneal
- hCE-1 human carboxyesterase-1
- mice intraperitoneal injection of LPS (50 ⁇ / ⁇ ).
- hCEl transgenic or wild type mice were treated with vehicle control or compound at 30 mg/kg, 10 mg/kg or 3mg/kg intraperitoneal ⁇ on days 0-1 1 . All mice were monitored for the development of arthritis and clinical signs, and were weighed, on days 0 and 3-12.
- the endpoints evaluated were incidence of arthritis, clinical score (front paws, rear paws and total) , paw thickness (front and rear) and body weight. I n the strain of mice used, the severity of the disease is less evident in the rear paws.
- a K-PD model (Jacqmin et al, J Pharmacokineti Pharmacodyn, 2007, 34(1 ) , pages 57-85) was fitted to Part A and Part B monocyte count data at Example 2 using NONMEM® (http://www.iconplc.com/innovation/solutions/nonmem/) , I CON'S non-linear, mixed effects modeling tool for Population Pharmacokinetic/ Pharmacodynamic ( PK/PD) data analysis, version 7.2 and Perl- speaks-NONMEM (PsN) version 3.4.2 (http://psn.sourceforge.net ) .
- the fitted model was subsequently utilized to simulate the monocyte count profile after every day, every other day and every three days dosing of 20mg and 40mg of the compound.
- Figures 7A/B Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering three every other day doses of 20 and 40 mg of compound.
- Figures 7C Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering three every day doses of 20 and 40 mg of compound. .
- Figures 7D Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering two doses of 20 and 40 mg of compound, each one every three days (Q3D strategy) .
- the total maximum study duration is approximately 10 weeks (not including any rescreen) . Following a screening period of up to 28 days, subjects will be randomised ( 1 : 1 ) to placebo or 40 mg of the compound orally-administered every other day for a period of 28 days (14 doses) . Subjects will be followed up for 7-14 days post final dose.
- I nclusion Criteria Type of subject and diagnosis including disease severity
- the subject must have a diagnosis of RA according to the 2010 ACR/ EULAR classification criteria for RA.
- Functional class I I I or I I I defined by the 1992 ACR Classification of Functional Status in RA.
- the subject must have a EULAR DAS 28-CRP of greater than 5.1 at screening.
- Disease duration > 6 months (time from onset of patient-reported symptoms of either pain or stiff ness or swelling in hands, feet or wrists).
- the subject must have a CRP serum level of > 5 mg/L at screening.
- the subject has had an inadequate response or intolerance of DMARDs (due to lack of efficacy or toxicity, after at least 8 weeks treatment) .
Abstract
The present invention relates to (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis. In particular, the present invention relates to the use of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate or a pharmaceutically acceptable salt thereof, in a novel dose or dosage regimen for the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis. The present invention is further directed to pharmaceutical compositions comprising said compound for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis by said novel dosage regimen. The present invention further relates to methods of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis through administration of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, under a novel dose or dosage regimen.
Description
DOSAGE REGI M EN
Fl ELD OF THE I NVENTI ON
The present invention relates to (S) -cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis. I n particular, the present invention relates to the use of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, in a novel dose and dosage regimen for the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis. The present invention is further directed to pharmaceutical compositions comprising said compound for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis by said novel dose or dosage regimen. The present invention further relates to methods of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis through administration of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, under a novel dose and dosage regimen.
BACKGROUN D TO TH E I NVENTI ON
Rheumatoid arthritis is a chronic inflammatory joint disease that affects approximately 1 % of the population in the industrialised world. I t affects approximately 3 times more women than men and onset is generally between 40 - 60 years of age. Rheumatoid arthritis is characterised by hyperplasia and inflammation of the synovial membrane, inflammation within the synovial fluid, and progressive destruction of the surrounding bone and cartilage. I t is a painful and debilitating condition , which can result in severe disability and ultimately affects a sufferer's ability to perform simple everyday tasks. Effects of rheumatoid arthritis vary between individuals, but the disease can progress very rapidly, causing swelling and damaging cartilage and bone around the joints. Any joint may be affected but most commonly the hands, feet and wrists.
I n rheumatoid arthritis, macrophages and monocytes become activated and infiltrate the synovial membranes, secreting inflammatory cytokines such as tumour necrosis factor alpha (TNFa) and interleukins, such as I L-1 , I L-6 and I L-8 (Li, 2013) . These cytokines activate fibroblast-like synoviocytes which produce enzymes that damage the bones and cartilage.
Disease-modifying antirheumatic drugs ( DMARDS) are the fundamental treatment for patients with rheumatoid arthritis. Methotrexate (MTX) is the current gold standard treatment and it effectively reduces clinical disease measures in a large population of patients. However, only 30% of RA patients will have low disease activity with MTX alone and in the population failing to respond, combination treatment with biological DMARDS targeted to cytokines, B-cells or T-cells, is the preferred treatment option (O'Dell, 2013) . A subset of these patients will still fail to achieve meaningful responses to treatment, or experience adverse events, and will continue to experience severely debilitating symptoms (Rubbert-Roth , 2009) .
Histone deacetylase (HDAC) inhibitors have been shown to be active in various models of inflammation (Lin, 2007; Nishida, 2004; Joosten , 201 1 ; Gauben , 2008) . The role of HDAC inhibitors in cancer, neurological diseases and immune disorders has been reviewed ( Falkenberg KJ et al, Nat Rev Drug Discov, 13, 673-691 , (2014) . However, there is a concern that, because of the pleiotropic activity, it may be challenging to obtain a therapeutic window wide enough to allow their extensive use in the treatment of chronic inflammatory diseases, such as rheumatoid arthritis.
The most studied HDAC inhibitor is the hydroxamic acid based compound vorinostat and this was approved in 2006 by the Food and Drug Association (FDA) for use in the treatment of cutaneous T-cell lymphoma (CTCL) . No HDAC inhibitor, however, including vorinostat, has been approved for use in the treatment of a chronic inflammatory or autoimmune disease, such as rheumatoid arthritis.
I nternational Patent Application Publication Number WO 2008/040934 discloses a series of HDAC inhibitors, one of which is (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate.
I n light of the above, it is clear that there is a current unmet need for more effective treatments for chronic inflammatory and/or autoimmune diseases, such as rheumatoid arthritis. I n particular, there exists a need for an efficacious treatment for chronic inflammatory and/or autoimmune diseases, such as rheumatoid arthritis that has a suitable safety profile.
SUMMARY OF TH E I NVENTI ON
I n a first aspect, the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
I n a further aspect, the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration twice a week, three times a week, or every other day.
I n a further aspect, the present invention provides a pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient.
I n yet a further aspect, the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-
(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg twice a week, three times a week, or every other day.
DESCRI PTI ON OF DRAW I NGS/ Fl GURES
FI G. 1 (a)— (f) Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers. Figure 1 shows the absolute monocyte counts over time obtained under the single ascending dose part of the study ( Part A) .
FI G. 2 (a)-(e) Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers. Figure 2 shows the absolute monocyte counts over time obtained under the multiple ascending dose part of the study ( Part B)
FI G. 3 Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)- 3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers. Figure 3 shows the concentration of acid in monocytes and non-monocytes obtained under the single ascending dose part of the study ( Part A)
FI G. 4 Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)- 3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers. Figure 4 shows the concentration of acid in monocytes and non-monocytes on Day 1 and Day 7 obtained under the multiple ascending dose part of the study (Part B)
FI G. 5 Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)- 3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers. Figure 5 shows the mean % change in acetylation of monocytes and non-monocytes obtained under the single ascending dose part of the study (Part A)
FI G. 6 Data from a clinical study evaluating (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)- 3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in healthy volunteers. Figure 6 shows thMean % Change in Acetylation of Monocytes and No n- Monocytes obtained under the multiple ascending dose part of the study (Part B)
FI G. 7A/B: Monocyte Count Profiling by K-PD Modelling. Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering three every other day doses of 20 and 40 mg of the compound of the invention .
FI G. 7C: Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering three every day doses of 20 and
40 mg of the compound of the invention .
FI G. 7D: Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering two doses of 20 and 40 mg of the compound of the invention , each one every three days (Q3D strategy) .
DETAI LED DESCRI PTI ON OF THE I NVENTI ON
DEFI NI TI ONS
As used herein , the term "DMARD" refers to "Disease-Modifying Anti-Rheumatic Drugs" and includes among others hydroxycloroquine, sulfasalazine, methotrexate, leflunomide, azathioprine, D- penicillamine, gold salts (oral) , gold salts (intramuscular) , minocycline, cyclosporine including cyclosporine A and topical cyclosporine, and TNF-inhibitors (e.g. etanercept ( ENBREL) , infliximab ( REM I CADE) , adalimumab (HUMI RA) , certolizumab pegol (CI MZI A) , and golimumab (SI MPONI ®)) , including salts, variants, and derivatives thereof . Exemplary DMARDs herein are non-biological, i.e. classic DMARDs, including azathioprine, chloroquine, hydroxychloroquine, leflunomide, methotrexate and sulfasalazine. I n one embodiment, the DMARD is methotrexate.
As used herein, the phrase "every other day" means on alternate days and thus in the context of a drug administration regime, there is a day when the dose is not administered between each day when a dose is administered. An example of an "every other day" dosing regimen would be dosing on Day 1 , Day 3, Day 5, Day 7, with no dosing on the days inbetween (i.e. Day 2, Day 4, Day 6, Day 8 etc) .
As used herein, the phrase "twice a week" means that in a typical week consisting of seven days, there are two days when a subject is administered a dose of the compound of the invention and five days when the subject is not administered a dose of the compound of the invention. An example of a "twice a week" dosing regimen would be dosing on a Monday (e.g. Day 1 ) and Thursday (e.g. Day 4) .
As used herein , the phrase "three times a week" means that in a typical week consisting of seven days, there are three days when a subject is administered a dose of the compound of the invention and four days when the subject is not administered a dose of the compound of the invention. An example of a "three times a week" dosing regimen would be dosing on a Monday (e.g. Day 1 ) , Wednesday (e.g. Day 3) and Friday (e.g. Day 5) .
As used herein , the term "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the compound in question and exhibit minimal undesired toxicological effects. These pharmaceutically-acceptable salts may be prepared in situ during the final isolation and purification of the compound, or by separately reacting the purified compound in its free acid or free base form with a suitable base or acid, respectively. Furthermore, pharmaceutically-acceptable salts of the compound in question , (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate, may be prepared during further processing of the free acid or base form, for example in situ during manufacture into a pharmaceutical composition.
As used herein, the term "treatment" refers to ameliorating or stabilising the specified condition, reducing or eliminating the symptoms of the condition, slowing or eliminating the progression of the condition, and preventing or delaying reoccurrence of the condition in a previously afflicted patient or subject.
As used herein, the term "subject" refers to an animal or human body.
References herein to "compound of the invention" mean (S)-cyclopentyl 2-cyclohexyl-2-(((6- (3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof.
(S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, may be in crystalline or amorphous form , each of which are included within the scope of the present invention. The most thermodynamically stable crystalline form is of particular interest. Crystalline forms may be characterised and differentiated using a number of conventional analytical techniques, including, but not limited to, X-ray powder diffraction (XRPD) , infrared spectroscopy ( I R) , Raman spectroscopy, differential scanning calorimetry ( DSC) , thermogravimetric analysis (TGA) and solid-state nuclear magnetic resonance (ssNMR) .
I n one embodiment, there is provided a crystalline solid state form of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate. I n a further embodiment, there is provided an amorphous form of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl) amino)acetate.
STATEMENT OF THE I NVENTI ON
I n a first aspect, the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day. I n one embodiment, administration is every other day.
I n a further aspect, the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration twice a week, three times a week, or every other day. I n one embodiment, administration is every other day.
I n a further aspect, the present invention provides a pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient.
I n a further aspect, the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-
(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg twice a week, three times a week, or every other day. I n one embodiment, administration is every other day.
I n yet a further aspect, the present invention provides the use of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate is for administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
(S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate is an inhibitor of histone deacetylase (HDAC) enzymes and is disclosed in I nternational Patent Application Publication Number WO 2008/040934 as Example 62. This compound has the following chemical structure:
(S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate is also known by the chemical name cyclopentyl (2S)-cyclohexyl[ ({ 6-[3- (hydroxyamino)-3-oxopropyl] pyridine-3-yl} methyl)amino] acetate.
This compound comprises an alpha amino acid ester moiety that facilitates delivery of the compound into the cell. The molecule comprising the alpha amino acid ester is not charged and is freely transported through the cell wall. Once inside the cell, the alpha amino acid ester undergoes hydrolysis by intracellular carboxylesterases, particularly hCE-1 , to the corresponding carboxylic acid, (S)-2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetic acid, shown below. Being charged, the acid is not readily transported out of the cell and thus the intracellular concentration of the inhibitor increases, leading to an increase in cellular potency and duration of action . The acid which is disclosed in I nternational Patent Application Publication Number WO 2008/040934 as Example 103 has the following chemical structure:
(S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino) -3-oxopropyl)pyridin-3- yl) methyl)amino)acetate has been the subject of an initial, Phase 1 clinical study in healthy human volunteers. I n this first clinical study, cohorts of healthy male volunteers received doses of the compound either as single ascending doses up to 60 mg (Part A of the study) or as multiple ascending doses of up to 40 mg once daily for a period of 7 days (Part B of the study) . A decision was made to not complete the final planned cohort at 60 mg in order to further investigate an unexpected pharmacodynamic observation. Following both single and multiple doses, the study team observed a significant reduction in the levels of circulating monocytes. I n Part A, from Cohort 2 ( 10 mg) onwards there was a decrease in the monocyte count observed at 4 hours and which showed a greater decrease at 24 hours post dosing. I n Part B, in both cohorts (20 mg and 40 mg, each once daily) , rapid depletion of monocytes was observed which then plateaued around Day 2.
The clinical significance of depleting circulating monocytes is poorly understood given the diverse functions of monocytes in the body and the complimentary roles of other immune cell types. However, it is thought that selective depletion of circulating monocytes (which may also be known by the term "isolated-monocytopaenia") may, for example, decrease a person's immunological defence mechanisms and thus make them more susceptible to infection.
Monocytes are a subset of circulating white blood cells and bloodstream monocytes are derived from the precursors in the bone marrow. Human monocytes are divided into subsets on the basis of surface CD14 and CD16 expression. The classical monocytes, CD14++ CD16" monocytes, are the most prevalent subset in human blood. The CD16+ monocytes comprises two subsets, CD14+CD16++ (non-classical) and CD14+ +CD16+ (intermediate) .
Monocytes are part of the host anti-microbial defence system . Recruitment of monocytes has been shown to contribute to the control and clearance of multiple infective agents by trafficking to sites of infections where they secrete cytokines and chemokines, by differentiation into cells such as macrophages and dendritic cells and by direct killing of microbes (Serbina, N.V. , Jia, T. , Hohl, T. M. & Pamer, E. G. , Monocyte-mediated defense against microbial pathogens. Annu. Rev. Immunol. 26, 421 - 452 (2008)) . Examples of pathogens controlled by monocytes include, but are not limited to, bacteria such as Listeria monocytogenes (Pamer, E.G. I mmune responses to Listeria monocytogenes. Nature Rev. Immunol. 4, 812-823 (2004) and Mycobacterium tuberculosis ( Peters, W. et al. Chemokine
receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 98, 7958-7963 (2001 )) , viruses such as Herpes simplex virus and West Nile virus (Lim, J. K. et al. Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in west nile virus encephalitis. J. Immunol. 1 86 , 471 -478 (201 1 )) , fungi such as Cryptococcus neoformans (Traynor, T. R. , Kuziel, W. A. , Toews, G. B. & Huffnagle, G. B. CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection. J. Immunol. 1 64 , 2021 -2027 (2000)) and protozoan parasites such as Toxoplasma gondii ( Dunay, I . R. et al. Gr1 + inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity 29, 306-317 (2008)) and Leishmania major ( Leon, B. , Lopez-Bravo, M. Ardavin, C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 2 , 519-531 (2007)) .
Following completion of the clinical study, we conducted a number of mechanistic studies to investigate the observed depletion of circulating monocytes.
We have now surprisingly found that (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate or a pharmaceutically acceptable salt thereof administered via a particular dosage regimen disclosed herein has the potential to provide an efficacious and safe treatment for a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis. I n particular, in a first aspect the present invention provides (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
I n a further aspect, the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration for at least 7 days in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
I n a further aspect the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-
(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration every other day in an amount of about 10 mg to about 40 mg.
I n a further aspect, the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)-
cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration twice a week, three times a week, or every other day.
I n a further aspect, the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration twice a week, three times a week, or every other day for at least 7 days.
I n a further aspect, the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration every other day.
I n a further aspect, the present invention provides a pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient.
I n yet a further aspect, the present invention provides the use of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate is for administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
I n yet a further aspect, the present invention provides a method of a chronic inflammatory and/or autoimmune disease, such as treating rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
I n yet a further aspect, the present invention provides a method of a chronic inflammatory and/or autoimmune disease, such as treating rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-
(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day for at least 7 days.
I n yet a further aspect, the present invention provides a method of a chronic inflammatory and/or autoimmune disease, such as treating rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S) -cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg every other day.
I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, is administered in an amount of about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, or 40 mg.
I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, is administered every other day in an amount of about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, or 40 mg.
I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, is administered twice a week in an amount of about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, or 40 mg.
I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, is administered three times a week in an amount of about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, or 40 mg.
I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, is administered in an amount of between 10 mg and 20 mg, between 20 mg and 30 mg, or between 30 mg and 40 mg.
I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, is administered every other day in an amount between 10 mg and 20 mg, between 20 mg and 30 mg, or between 30 mg and 40 mg.
I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, is administered twice a week in an amount between 10 mg and 20 mg, between 20 mg and 30 mg, between 30 mg and 40 mg, between 40 mg and 50 mg, or between 50 mg and 60 mg.
I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, is
administered three times a week in an amount between 10 mg and 20 mg, between 20 mg and 30 mg, or between 30 mg and 40 mg.
I n a further embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof, is administered every other day in an amount of about 40 mg.
I n particular, in one embodiment the present invention provides (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration every other day in an amount of about 40 mg.
I n a further embodiment, the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises about 40 mg of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration every other day.
I n a further embodiment, the present invention provides a pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 40 mg, and a pharmaceutically acceptable excipient.
I n yet a further aspect, the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 40 mg every other day.
Our data suggests that dosing the compound of the invention according to a regimen as described herein (e.g. every other day dosing) within the dose range specified permits monocyte recovery during each dosing interval. Thus, not only is the monocyte depletion reversible but that levels can recover either fully or partially to an acceptable level within the interval between doses and hence prior to administration of a subsequent dose. Thus, dosing according to a regimen described herein (e.g. every other day dosing) within the specified range disclosed herein prevents prolonged depletion of this population of leukocytes. The dosage regimens of the present invention thus aim to minimise the potentially adverse effects of sustained monocyte depletion, while advantageously maintaining therapeutic efficacy with the compound of the invention.
I ncomplete or partial recovery of monocytes under a dosing strategy according to the present invention (i.e. such that there remains a degree of monocyte depletion but the levels of monocytes remain above that which may trigger adverse effects of sustained monocyte depletion) may enhance
the therapeutic benefit in the treatment of a chronic inflammatory and/or autoimmune disease, in particular rheumatoid arthritis. Monocytes are central to the pathophysiology of rheumatoid arthritis. They are present in large numbers in inflamed joints and contribute to pathology through the release of cytokines and chemokines which drive inflammation and also via maturation into inflammatory macrophages and osteoclasts (C. A. Roberts et al, Frontiers in I mmunology, Vol. 6, Article 571 , (2015)) . Monocytes in the circulation of rheumatoid arthritis patients have also been shown to have an activated phenotype.
I n one embodiment, administration of a compound of the invention according to a dosing regimen described herein in an amount of about 10 mg to about 40 mg permits recovery of circulating monocytes prior to administration of the next dose, wherein recovery is between 30% and 100% (e.g. greater than 30% , 40% , 50% , 60% , 70% , 80% , or 90% ) of the normal baseline level prior to treatment with a compound of the invention .
I n a further embodiment, administration of a compound of the invention every other day in an amount of about 20 mg to about 40 mg permits recovery of circulating monocytes prior to administration of the next dose, wherein recovery is between 50% and 80% (e.g. greater than 50% , 60% , or 70% ) of the normal baseline level prior to treatment with a compound of the invention.
I n a further embodiment, administration of a compound of the invention every other day in an amount of about 20 mg permits recovery of circulating monocytes prior to administration of the next dose, wherein recovery is between 60% and 80% (e.g. greater than 60% , or 70% ) of the normal baseline level pre-treatment with a compound of the invention.
I n a further embodiment, administration of a compound of the invention every other day in an amount of about 40 mg permits recovery of circulating monocytes prior to administration of the next dose, wherein recovery is between 50% and 70% (e.g. greater than 50% or 60%) of the normal baseline level prior to treatment with a compound of the invention.
Furthermore, we have also surprisingly found from a mechanistic study in a mouse model that the effect observed, i.e. partial or complete recovery of monocyte levels before subsequent dosing, is reproducible following multiple doses. Therefore, prolonged use of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis according to a dosage regimen described herein is not likely to result in cumulative monocytopaenia, in which the magnitude of monocyte recovery diminishes over time and with each subsequent dose.
Whilst the administration of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day may provide a safer therapy for the treatment of a chronic inflammatory and/or
autoimmune disease, such as rheumatoid arthritis, this administration strategy may also maintain or enhance efficacy.
MEDI CAL USE
The dosage regimens described herein are for use in the treatment of inflammatory and/or autoimmune diseases in a human or animal subject. I n one embodiment, the dosage regimens described herein are for use in the treatment of chronic inflammatory and/or autoimmune diseases in a human or animal subject. I n one embodiment, the subject is a human.
Autoimmune and/or inflammatory conditions (e.g. chronic autoimmune and/or inflammatory conditions) include rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, pulmonary arterial hypertension (PAH) , multiple sclerosis, inflammatory bowel disease (Crohn's disease and ulcerative colitis) , asthma, chronic obstructive airways disease, pneumonitis, myocarditis, pericarditis, myositis, eczema, dermatitis (including atopic dermatitis) , alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis, hypercholesterolemia, atherosclerosis, Alzheimer's disease, depression, Sjogren's syndrome, sialoadenitis, central retinal vein occlusion, branched retinal vein occlusion , I rvine-Gass syndrome (post cataract and post-surgical) , retinitis pigmentosa, pars planitis, birdshot retinochoroidopathy, epiretinal membrane, cystic macular odema, parafoveal telengiectasis, tractional maculopathies, vitreomacular traction syndromes, retinal detachment, neuroretinitis, idiopathic macular odema, retinitis, dry eye (keratoconjunctivitis Sicca) , vernal keratoconjunctivitis, atopic keratoconjunctivitis, uveitis (such as anterior uveitis, pan uveitis, posterior uveitis, uveitis- associated macular odema) , scleritis, diabetic retinopathy, diabetic macula odema, age-related macular dystrophy, hepatitis, pancreatitis, primary biliary cirrhosis, sclerosing cholangitis, Addison's disease, hypophysitis, thyroiditis, type I diabetes, giant cell arteritis, nephritis including lupus nephritis, vasculitis with organ involvement such as glomerulonephritis, vasculitis including giant cell arteritis, Wegener's granulomatosis, Polyarteritis nodosa, Behcet's disease, Kawasaki disease, Takayasu's Arteritis, pyoderma gangrenosum, vasculitis with organ involvement, acute rejection of transplanted organs, and juvenile idiopathic arthritis (e.g. systemic-onset, persistent or extended oligoarthritis, RF- negative polyarthritis, RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated) .
I n another embodiment, the chronic autoimmune and/or inflammatory condition is a systemic inflammatory disorder such as rheumatoid arthritis, osteoarthritis, psoriasis, systemic lupus erythematosus, multiple sclerosis or inflammatory bowel disease (Crohn's disease and ulcerative colitis) .
The dose and dosage regimens described herein may further find use in the treatment of viral infections and cancer. Viral infections include herpes simplex infections and reactivations, cold sores, herpes zoster infections and reactivations, chickenpox, shingles, human papilloma virus (HPV) , human immunodeficiency virus (HI V) , cervical neoplasia, adenovirus infections, including acute respiratory disease, poxvirus infections such as cowpox and smallpox and African swine fever virus. I n one embodiment, the viral infection is HI V infection.
Cancers include haematological (such as leukaemia, lymphoma and multiple myeloma) , epithelial including lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and neurological tumours. Also brain cancer (gliomas) , glioblastomas, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast cancer, inflammatory breast cancer, colorectal cancer, Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, ependymoma, medulloblastoma, colon cancer, head and neck cancer, kidney cancer, lung cancer, liver cancer, melanoma, squamous cell carcinoma, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma cancer, osteosarcoma, giant cell tumor of bone, thyroid cancer, lymphoblastic T-cell leukaemia, chronic myelogenous leukaemia, chronic lymphocytic leukaemia, hairy-cell leukaemia, acute lymphoblastic leukaemia, acute myelogenous leukaemia, chronic neutrophilic leukaemia, acute lymphoblastic T-cell leukaemia, plasmacytoma, immunoblastic large cell leukaemia, mantle cell leukaemia, multiple myeloma, megakaryoblastic leukaemia, acute megakaryocytic leukaemia, promyelocytic leukaemia, mixed lineage leukaaemia, erythroleukaemia, malignant lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, lymphoblastic T-cell lymphoma, Burkitt's lymphoma, follicular lymphoma, neuroblastoma, bladder cancer, urothelial cancer, vulval cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GI ST (gastrointestinal stromal tumor) , NUT-midline carcinoma and testicular cancer.
I n one embodiment, the cancer is a leukaemia, for example a leukaemia selected from acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia and mixed lineage leukaemia (MLL) .
The use of a compound of the invention via a novel dosage regimen in the treatment of rheumatoid arthritis is of particular interest. Rheumatoid arthritis is an autoimmune disease characterised by chronic inflammation of synovial tissue, leading to destruction of the joint architecture. I t is a painful and debilitating condition, which can result in severe disability and ultimately affects a sufferer's ability to perform simple everyday tasks. Effects of rheumatoid arthritis vary between individuals, but the disease can progress very rapidly, causing swelling and damaging cartilage and bone around the joints. Any joint may be affected but most commonly the hands, feet and wrists.
I n rheumatoid arthritis, macrophages and monocytes become activated and infiltrate the synovial membranes, secreting inflammatory cytokines such as tumour necrosis factor alpha (TNFa) and interleukins, such as I L-1 , I L-6 and I L-8 (Li, 2013) . These cytokines activate fibroblast-like synoviocytes which produce enzymes that damage the bones and cartilage.
I n one embodiment, the dosage regimens described herein are for use in the treatment of moderate to severe rheumatoid arthritis. A commonly used method for classifiying disease activity in rheumatoid arthritis patients is Disease Activity Score of 28 joints (DAS 28). A DAS28 of <3.2 is
classified as inactive. A DAS28 of > 3.2 but < 5.1 is classified as moderate rheumatoid arthritis. A DAS28 of > 5.1 is classified as severe.
I n a further embodiment, the dosage regimens described herein are for use in the treatment of severe rheumatoid arthritis. I n a further embodiment, the dosage regimens described herein are for use in the treatment of severe rheumatoid arthritis, i.e. wherein the patient has a DAS28 of > 5.1 . I n yet a futher embodiment, the dosage regimens described herein are for use in the treatment of subjects with severe rheumatoid arthritis despite treatment with existing therapies, such as conventional and biological disease modifying anti-rheumatic drugs ( DMARDs) .
I n a separate and further aspect of the invention, there is provided the compound of the invention for use in the treatment of autoimmune and/or inflammatory conditions. I n a further aspect of the present invention, there is provided a method of treatment of an autoimmune and/or inflammatory condition , which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention . I n yet a further aspect, the present invention is directed to the use of a compound of the invention in the manufacture of a medicament for use in the treatment of an autoimmune and/or inflammatory condition.
I n one embodiment, there is provided the compound of the invention for use in the treatment of arthritis, for example rheumatoid arthritis (e.g. severe rheumatoid arthritis) .
I n a further aspect of the present invention, there is provided a method of treatment of arthritis (for example rheumatoid arthritis (e.g. severe rheumatoid arthritis) , which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention. I n yet a further aspect, the present invention is directed to the use of a compound of the invention in the manufacture of a medicament for use in the treatment of arthritis (for example rheumatoid arthritis (e.g. severe rheumatoid arthritis)) .
Moreover, data disclosed herein (e.g. Example 2) demonstrate that the compound of the invention possesses monocyte-depletion activity (e.g. depletion of circulating blood monocytes) separate from an HDAC inhibitory effect, and thus may be used to effectively deplete circulating blood monocytes. This property may be exploited in the treatment or prevention of diseases (e.g. autoimmune and/or inflammatory diseases, and cancers) where monocytes are known to play an important role in the development and progression of the disease. I n one embodiment,
administration of the compound of the invention results in depletion of circulating blood monocytes. Mechanistic studies reported herein demonstrate that the surprising monocyte-depleting activity of the compound of the invention is not observed with non-targeted HDAC inhibitors (SAHA was used in Example 3, Study 3) . This effect was, however, observed for an analogue of the compound of the invention.
I n one aspect, there is provided an HDAC inhibitor comprising a carboxylesterase sensitive motif for use in the treatment of prevention of an autoimmune and/or inflammatory condition , wherein the HDAC inhibitor is administered at a dose which results in depletion of circulating blood monocytes.
As used herein the term "HDAC inhibitor comprising a carboxylesterase sensitive motif" refers to a covalent conjugate of an HDAC inhibitor and an alpha amino acid ester, wherein the ester group of the alpha amino acid ester is hydrolysable by one or more intracellular carboxylesterases to the corresponding carboxylic acid. Covalent conjugates of an HDAC inhibitor and an alpha amino acid ester are disclosed in, for example, WO2006/ 1 17567, WO2006/ 1 17549, WO2008/040934, WO2008/053131 , WO2009/ 106848, WO2006/ 1 17548, WO2008/053131 , WO2008/040934, WO2010/097586, WO2012/025701 , , and each of these covalent conjugates (e.g. tefinostat, which is also known as CHR-2845, or a pharmaceutically acceptable salt thereof) are incorporated herein by reference and may be utilised in the methods of treatment/medical uses described herein below.
I n one aspect of the invention, there is provided the compound of the invention for use in the treatment or prevention of an autoimmune and/or inflammatory disease, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes. I n a further aspect of the present invention, there is provided a method of treatment or prevention of an autoimmune and/or inflammatory condition, which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention , wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes. I n yet a further aspect, the present invention is directed to the use of a compound of the invention in the manufacture of a medicament for use in the treatment or prevention of an autoimmune and/or inflammatory condition, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes. I n a further embodiment, depletion of circulating blood monocytes may be prolonged depletion, i.e. for at least the duration of the treatment period with the compound of the invention . I n a further embodiment, administration of a compound of the invention results in depletion of circulating monocytes to between 10% and 90% (e.g. between 10% and 30% , or less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level prior to treatment with a compound of the invention. I n a further embodiment, administration of a compound of the invention results in depletion of circulating monocytes to between 10% and 30% of the normal baseline level prior to treatment with a compound of the invention .
I n a further aspect of the invention, there is provided a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject comprising administration to the subject in need thereof a therapeutically effective amount of an HDAC inhibitor comprising a carboxylesterase sensitive motif. I n a further aspect of the invention, there is provided a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject comprising administration to the subject in need thereof a therapeutically effective amount of a compound of the invention. I n one embodiment, the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer. I n a further embodiment, the present invention provides a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject comprising administration to the
subject in need thereof a therapeutically effective amount of a compound of the invention, wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease, and wherein the method decreases, reduces, suppresses, limits, or inhibits an undesired or aberrant immune or inflammatory component of an autoimmune and/or inflammatory disease.
I n a further aspect of the invention, there is provided a method of modulating monocytes (e.g. circulating blood monocytes) in a subject comprising administration to the subject in need thereof a therapeutically effective amount of an HDAC inhibitor comprising a carboxylesterase sensitive motif. I n a further aspect of the invention, there is provided a method of modulating monocytes (e.g. circulating blood monocytes) in a subject comprising administration to the subject in need thereof a therapeutically effective amount of a compound of the invention . I n one embodiment, the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer. I n a further embodiment, the present invention provides a method of modulating monocytes (e.g. circulating blood monocytes) in a subject comprising administration to the subject in need thereof a therapeutically effective amount of a compound of the invention , wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease, and wherein the method decreases, reduces, suppresses, limits, or inhibits an undesired or aberrant immune or inflammatory component of an autoimmune and/or inflammatory disease.
I n a further aspect, the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject. I n one embodiment, the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer. I n a further embodiment, the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes)and/or macrophages and/or dendritic cells in a subject who has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer. I n a further embodiment, the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject, wherein the method decreases, reduces, suppresses, limits, or inhibits an undesired or aberrant immune or inflammatory component of an autoimmune and/or inflammatory disease. I n one embodiment, the subject whose monocytes and/or macrophages and/or dendritic cells will be modulated following administration of a compound of the invention is at risk of developing or has been diagnosed with an autoimmune and/or inflammatory condition as set forth herein.
I n a further aspect, the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) in a subject. I n one embodiment, the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer. I n a further embodiment, the present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) in a subject who has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer. I n a further embodiment, the
present invention provides a compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) in a subject, wherein the method decreases, reduces, suppresses, limits, or inhibits an undesired or aberrant immune or inflammatory component of an autoimmune and/or inflammatory disease. I n one embodiment, the subject whose monocytes will be modulated following administration of a compound of the invention is at risk of developing or has been diagnosed with an autoimmune and/or inflammatory condition as set forth herein.
The present invention is further directed to a method for attenuating monocyte hyperactivity in a subject (e.g. a human subject) comprising administering to the subject in need thereof a therapeutically effective amount of an HDAC inhibitor comprising a carboxylesterase sensitive motif, wherein monocyte hyperactivity is attenuated. The present invention is further directed to a method for attenuating monocyte hyperactivity in a subject (e.g. a human subject) comprising administering to the subject in need thereof a therapeutically effective amount of a compound of the invention, wherein monocyte hyperactivity is attenuated. I n a further aspect, the present invention provides a compound of the invention for use in attenuating monocyte hyperactivity in a subject (e.g. a human subject) . I n one embodiment, the subject with monocyte hyperactivity is at risk of developing or has been diagnosed with an autoimmune and/or inflammatory disease as set forth herein .
I n one embodiment, the subject is a human subject.
As used herein, the term "at risk" refers to those subjects who have a high probability of developing a disease, determined by, for example, genetic predisposition (i.e. family history and/or detection of one or more genetic polymorphisms or mutations) , biomarker analysis and/or imaging.
As used herein, the term "modulating, depleting or attenuating" refers to decreasing or reducing (e.g. the amount of circulating blood monocytes) either permanently (e.g. apoptosis) or transiently (e.g. margination or retention in tissues and/or decreased production) . Monocyte levels, unless otherwise specified, may be decreased or reduced to between 10% and 90% (e.g. less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level prior to treatment with a compound of the invention . The normal baseline level may be determined by performing a Full Blood Count ( FBC) test. FBC is a well-known, standard test that provides information about the types of cells in a subject's blood, for example cell count for each cell type. I n one embodiment, the monocyte level, unless otherwise specified, may be decreased or reduced to between 10% and 90% (e.g. between 10% and 30% , or less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal monocyte range of 0.2 - 1 .5 x 109 cells/L. Depletion or reduction of monocytes refers to depletion or reduction of one or more of the three recognised subsets of monocytes: classical, non-classical and intermediate. I n one embodiment, all subsets of monocytes are depleted/reduced/modulated/ attenuated.
Many autoimmune and inflammatory diseases have been linked to over-activation of the immune system , and the dysregulation of monocyte and macrophage functions (see, for example, S T Gren et al, Role of Monocytes and I ntestinal Macrophages in Crohn's Disease and Ulcerative Colitis, I nflamm Bowel Dis, Vol 22, No. 8, August 2016) . Furthermore, inflammation has been suggested to
play a key role in the pathogenesis of atrial fibrillation (AF) with one study investigating whether peripheral monocyte TLR expression was associated with AF presence, and recurrence of AF after cryoablation, as a reflection of inflammatory status (see K M Gurses et al, Monocyte Toll-Like Receptor Expression in Patients with Atrial Fibrillation, Am J Cardiol, 2016, 1 17, p1463-1467) .
I n one embodiment, autoimmune and/or inflammatory diseases that may be treated or prevented with a compound of the invention, via depletion/modulation/reduction/attenuation of monocytes (e.g. circulating blood monocytes) include inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , and primary biliary cirrhosis ( PBC) . I n a further embodiment, autoimmune and/or inflammatory diseases that may be treated with a compound of the invention, via depletion/modulation/reduction/attenuation of monocytes (e.g. circulating blood monocytes) include psoriatic arthritis ( PsA) , ankylosing spondylitis (AS) , atrial fibrillation, and juvenile idiopathic arthritis (e.g. systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated) . I n a further embodiment, the autoimmune and/or inflammatory disease that may be treated with a compound of the invention, via depletion/modulation/reduction/attenuation of monocytes is rheumatoid arthritis. I n a further embodiment, the autoimmune and/or inflammatory disease that may be treated with a compound of the invention, via depletion/modulation/reduction/attenuation of monocytes is multiple sclerosis. I n a further embodiment, the autoimmune and/or inflammatory disease that may be treated with a compound of the invention , via depletion/modulation/reduction/attenuation of monocytes is atherosclerosis. I n a further embodiment, the compound of the invention, via depletion/modulation/reduction/attenuation of monocytes (e.g. circulating blood monocytes) may be useful in the treatment of monocytosis.
I n a further aspect of the present invention, the capability of the compound of the invention to deplete monocytes may be useful for the treatment of monocytosis. Monocytosis, which occurs during chronic inflammation , is an increase in the number of monocytes circulating in the blood. I n one embodiment, a monocyte count above 950/μΙ_ is regarded as monocytosis. I n one embodiment, there is provided a compound of the invention for use in the treatment of monocytosis. I n a further embodiment, there is provided a compound of the invention for use in the treatment of monocytosis wherein the compound of the invention results in the depletion of monocytes (e.g. circulating blood monocytes) . I n a further aspect of the present invention, there is provided a method of treatment of monocytosis, which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention . I n a further aspect of the present invention , there is provided a method of treatment of monocytosis, which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes. I n yet a further aspect, the present invention is directed to the use of a compound of the invention in the manufacture of a medicament for use in the treatment of monocytosis. I n yet a further aspect, the
present invention is directed to the use of a compound of the invention in the manufacture of a medicament for use in the treatment of monocytosis, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes. A subject (e.g. a human subject) diagnosed with monocytosis may have an autoimmune and/or inflammatory condition.
Embodiment 1 : The compound of the invention for use in the treatment or prevention of an autoimmune and/or inflammatory disease and/or cancer in a subject, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes and/or macrophages and/or dendritic cells.
Embodiment 2: The compound for use according to Embodiment 1 , wherein depletion of circulating blood monocytes may be prolonged depletion, i.e. for at least the duration of the treatment period with the compound of the invention .
Embodiment 3: The compound for use according to Embodiment 1 or 2, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 90% (e.g. between 10% and 30% , or less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with a compound of the invention .
Embodiment 4: The compound for use according to Embodiment 3, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 30% of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention.
Embodiment 5: The compound for use according to any of Embodiments 1 to 4, wherein the autoimmune and/or inflammatory disease is selected from the group consisting of : inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , primary biliary cirrhosis ( PBC) , psoriatic arthritis ( PsA) , ankylosing spondylitis (AS) , atrial fibrillation, juvenile idiopathic arthritis (e.g. systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated) , rheumatoid arthritis, multiple sclerosis and atherosclerosis.
Embodiment 6: The compound for use according to any of Embodiments 1 to 5, wherein the subject is a human subject.
Embodiment 7: The compound for use according to any of Embodiments 1 to 6, wherein the compound of the invention is (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate.
Embodiment 8: The compound for use according to any of Embodiments 1 to 7, wherein the use is for the treatment of an autoimmune and/or inflammatory disease.
Embodiment 9: The compound for use according to any of Embodiments 1 to 8, wherein the compound of the invention results in depletion of one or more subsets (classical, non-classical and intermediate) of circulating blood monocytes.
Embodiment 10: The compound for use according to any of Embodiments 1 to 9, wherein the compound of the invention results in depletion of all subsets (classical, non-classical and intermediate) of circulating blood monocytes.
Embodiment 1 1 : The compound of the invention for use in a method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject.
Embodiment 12: The compound for use according to Embodiment 1 1 , wherein the monocyte (e.g. circulating blood monocytes) level is decreased or reduced to between 10% and 90% (e.g. less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention.
Embodiment 13: The compound for use according to Embodiment 12, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 30% of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention .
Embodiment 14: The compound for use according to any of Embodiments 1 1 to 13, wherein the subject is a human subject.
Embodiment 15: The compound for use according to any of Embodiments 1 1 to 14, wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer.
Embodiment 16: The compound for use according to any of Embodiments 1 1 to 15, wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease and the compound of the invention is for the treatment of said disease.
Embodiment 17: The compound for use according to Embodiment 15 or 16, wherein the autoimmune and/or inflammatory disease is selected from the group consisting of : inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , primary biliary cirrhosis (PBC) , psoriatic arthritis (PsA) , ankylosing spondylitis (AS) , atrial fibrillation , juvenile idiopathic arthritis (e.g. systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated) , rheumatoid arthritis, multiple sclerosis and atherosclerosis.
Embodiment 18: The compound for use according to any of Embodiments 1 1 to 17, wherein the compound of the invention is (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate.
Embodiment 19: The compound for use according to any of Embodiments 1 1 to 18, wherein the compound of the invention results in modulation of one or more subsets (classical, non-classical and intermediate) of circulating blood monocytes.
Embodiment 20: The compound for use according to any of Embodiments 1 1 to 19, wherein the compound of the invention results in depletion of all subsets (classical, non-classical and intermediate) of circulating blood monocytes.
Embodiment 21 : A method of treatment or prevention of an autoimmune and/or inflammatory condition and/or cancer, which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound of the invention, wherein the compound of the invention is administered at a dose which results in depletion of circulating blood monocytes.
Embodiment 22: A method of treatment according to Embodiment 21 , wherein depletion of circulating blood monocytes may be prolonged depletion, i.e. for at least the duration of the treatment period with the compound of the invention .
Embodiment 23: A method of treatment according to Embodiment 21 or 22, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 90% (e.g. between 10% and 30% , or less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with a compound of the invention .
Embodiment 24: A method of treatment according to Embodiment 23, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 30% of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention.
Embodiment 25: A method of treatment according to any of Embodiments 21 to 24, wherein the autoimmune and/or inflammatory disease is selected from the group consisting of : inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , primary biliary cirrhosis ( PBC) , psoriatic arthritis ( PsA) , ankylosing spondylitis (AS) , atrial fibrillation, juvenile idiopathic arthritis (e.g. systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated) , rheumatoid arthritis, multiple sclerosis and atherosclerosis.
Embodiment 26: A method of treatment according to any of Embodiments 21 to 25, wherein the subject is a human subject.
Embodiment 27: A method of treatment according to any of Embodiments 21 to 26, wherein the compound of the invention is (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate.
Embodiment 28: A method of treatment according to any of Embodiments 21 to 27, wherein the method of treatment is of an autoimmune and/or inflammatory disease.
Embodiment 29: A method of treatment according to any of Embodiments 21 to 28, wherein the compound of the invention results in depletion of one or more subsets (classical, non-classical and intermediate) of circulating blood monocytes.
Embodiment 30: A method of treatment according to any of Embodiments 21 to 29, wherein the compound of the invention results in depletion of all subsets (classical, non-classical and intermediate) of circulating blood monocytes.
Embodiment 31 : A method of modulating monocytes (e.g. circulating blood monocytes) and/or macrophages and/or dendritic cells in a subject comprising administration to the subject in need thereof a therapeutically effective amount of a compound of the invention.
Embodiment 32: A method of modulating according to Embodiment 31 , wherein the monocyte (e.g. circulating blood monocytes) level in a subject is decreased or reduced to between 10% and 90% (e.g. less than 20% , 30% , 40% , 50% , 60% , 70% , or 80% ) of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention.
Embodiment 33: A method of modulating according to Embodiment 32, wherein administration of the compound of the invention results in depletion of circulating monocytes to between 10% and 30% of the normal baseline level (optionally determined by performing a Full Blood Count) determined prior to treatment with the compound of the invention .
Embodiment 34: A method of modulating according to any of Embodiments 31 to 33, wherein the subject is a human subject.
Embodiment 35: A method of modulating according to any of Embodiments 31 to 34, wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease and/or cancer.
Embodiment 36: A method of modulating according to any of Embodiments 31 to 35, wherein the subject has been diagnosed with an autoimmune and/or inflammatory disease and the compound of the invention is for the treatment of said disease.
Embodiment 37: A method of modulating according to Embodiment 35 or 36, wherein the autoimmune and/or inflammatory disease is selected from the group consisting of : inflammatory bowel disease (Crohn's disease and ulcerative colitis) , non-alcoholic steato hepatitis (NASH) , primary biliary cirrhosis ( PBC) , psoriatic arthritis ( PsA) , ankylosing spondylitis (AS) , atrial fibrillation, juvenile idiopathic arthritis (e.g. systemic-onset, persistent or extended oligoarthritis, RF-negative polyarthritis,
RF-positive polyarthritis, psoriatic, enthesitis-related, and undifferentiated) , rheumatoid arthritis, multiple sclerosis and atherosclerosis.
Embodiment 38: A method of modulating according to any of Embodiments 31 to 37, wherein the compound of the invention is (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate.
Embodiment 39: A method of modulating according to any of Embodiments 31 to 38, wherein the compound of the invention results in modulation of one or more subsets (classical, non-classical and intermediate) of circulating blood monocytes.
Embodiment 40: A method of modulating according to any of Embodiments 31 to 39, wherein the compound of the invention results in depletion of all subsets (classical, non-classical and intermediate) of circulating blood monocytes.
PHARMACEUTI CAL COMPOSI TI ONS/ ROUTES OF ADMI Nl STRATI ON/ DOSAGES
While it is possible that for use in therapy a compound of the invention may be administered as the raw chemical, it is common to present the active ingredient as a pharmaceutical composition. I n one embodiment, the pharmaceutical composition comprising a compound of the invention further comprises a pharmaceutically acceptable excipient. I n a further embodiment, the pharmaceutical composition comprises a compound of the invention and one or more pharmaceutically acceptable excipient(s) .
I n one embodiment, there is provided a pharmaceutical composition comprising (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient. I n a further embodiment, there is provided a pharmaceutical composition comprising (S) -cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin- 3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient.
I n one embodiment, the pharmaceutical composition comprises (S)-cyclopentyl 2-cyclohexyl- 2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 40 mg.
As would be expected, any excipients utilised must be pharmaceutically acceptable and be compatible with the other components (other excipients and the active ingredient) of the composition. I n accordance with another aspect of the invention there is also provided a process for the preparation of a pharmaceutical composition including admixing (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, with a pharmaceutically acceptable excipient.
Since (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, is intended for use in pharmaceutical compositions it will be readily understood that the compound is preferably provided in substantially pure form , for example, at least 85% pure, especially at least 98% pure (% in a weight for weight basis) .
Pharmaceutical compositions for use in the treatment of rheumatoid arthritis according to the present invention may be administered orally. Such compositions may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the excipient(s) . Pharmaceutical compositions adapted for oral administration may be presented as discrete units such as tablets or capsules, powders or granules, solutions or suspensions in aqueous
or non-aqueous liquids, edible foams or whips, or oil-in-water liquid emulsions or water-in-oil liquid emulsions. I n one embodiment, the pharmaceutical composition is adapted for oral administration.
I n one embodiment, the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by oral administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
I n one embodiment, the present invention provides (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by oral administration every other day in an amount of about 10 mg to about 40 mg. I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate is administered orally in an amount of about 40 mg. I n another embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate is administered orally in an amount of about 20 mg.
I n a further embodiment, the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for oral administration twice a week, three times a week, or every other day.
I n a further embodiment, the present invention provides a pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for oral administration every other day. I n another embodiment, the pharmaceutical composition comprises about 40 mg of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof. I n another embodiment, the pharmaceutical composition comprises about 20 mg of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof.
I n a further embodiment, the present invention provides a pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a pharmaceutically acceptable excipient, wherein the pharmaceutical
composition is for oral administration. I n another embodiment, the pharmaceutical composition comprises about 40 mg of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof. I n another embodiment, the pharmaceutical composition comprises about 20 mg of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof.
I n yet a further embodiment, the present invention provides the use of (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate is for oral administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
I n yet a further embodiment, the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises orally administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6- (3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
I n yet a further embodiment, the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises orally administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6- (3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg every other day.
I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate is administered orally in an amount of about 40 mg. I n another embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate is administered orally in an amount of about 20 mg.
I n yet a further embodiment, the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises orally administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6- (3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day, wherein (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, is in the form of a pharmaceutical composition.
I n yet a further embodiment, the present invention provides a method of treating a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, which method comprises orally administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6- (3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg every other day, wherein (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, is in the form of a pharmaceutical composition . I n one embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate is administered orally in an amount of about 40 mg. I n another embodiment, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate is administered orally in an amount of about 20 mg.
Pharmaceutical compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Preferred unit dosage compositions are those containing the dose for an entire day or sub-dose, or an appropriate fraction thereof, of an active ingredient. Unit doses that contain a sub-dose of the recommended dose for a day may therefore be administered more than once in order to make up the total dose for a day. For example, if a dose on a particular day is 40 mg, this may be contained in one unit or in multiple units (e.g. 4 units each comprising 10 mg of active ingredient) , wherein a unit may for example be a tablet or capsule. I n one embodiment, the pharmaceutical composition is in unit dosage form . I n a further embodiment, the unit dosage form is a tablet or a capsule.
Powders suitable for incorporating into tablets or capsules may be prepared by reducing a compound of the invention to a suitable fine size (e.g. by micronisation) and mixing with a similarly prepared pharmaceutical excipient such as an edible carbohydrate, for example, starch or mannitol. Flavouring, preservative, dispersing and colouring agents, for example, may also be present.
Capsules may be made by preparing a powder mixture and filling formed gelatin sheaths.
Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate, sodium stearate, sodium oleate, sodium benzoate, sodium acetate, sodium chloride and the like, or solid polyethylene glycol can be added to the powder mixture before the filling operation . A diluent, such as microcrystalline cellulose can also be added. A disintegrating or solubilising agent such as agar- agar, starch, methyl cellulose, bentonite, xanthan gum , calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested. Moreover, suitable binders, sweetening agents, flavours, and colouring agents can also be incorporated into the mixture. Suitable binders include starch (e.g. pregelatinised starch) , gelatin , natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
I n one embodiment, each capsule comprises a compound of the invention, pregelatinised starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate. I n a further
embodiment, each capsule comprises 10 to 40 mg of a compound of the invention , pregelatinised starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate. I n a further embodiment, each capsule comprises 20 mg of a compound of the invention, pregelatinised starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate. I n a further embodiment, each capsule comprises 40 mg of a compound of the invention, pregelatinised starch, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate.
Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin , a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. A compound of the invention can also be combined with a free flowing inert excipient and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.
I n one embodiment, a tablet formulation may comprise a compound of the invention and microcrystalline cellulose, mannitol, croscarmellose sodium , hypromellose and magnesium stearate.
Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavoured aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilisers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavour additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
Where appropriate, dosage unit compositions for oral administration can be microencapsulated.
COMBI NATI ON THERAPY
I n certain embodiments, (S) -cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3- oxopropyl)pyridin-3-yl) methyl)amino)acetate or a pharmaceutically acceptable salt thereof for use according to the present invention may be administered in combination with one or more (e.g. two)
other therapeutic agents that treat a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis.
For the treatment of rheumatoid arthritis, the additional therapeutic agent(s) include, for example, immunosuppressive agents, non-steroidal anti-inflammatory drugs (NSAI Ds) , disease modifying anti-rheumatic drugs (DMARDs) , such as methotrexate (MTX) , anti-B-cell surface marker antibodies, such as anti-CD20 antibodies (e.g. rituximab) , TNF-alpha-inhibitors (e.g. infliximab, adalimumab, certolizumab pegol, golimumab, or etanercept) , anti-I L-6 antibodies (e.g. tocilizumab, sirukumab) , anti-GM-CSF antibodies (e.g. an antibody having amino acid sequence and DNA sequence as provided in Figure 1 of WO 2014/044768) , corticosteroids (e.g. prednisone,
prednisolone, methylprednisolone, or dexamethasone) , and co-stimulatory modifiers, or any combination thereof. I n one embodiment, the additional therapeutic agent(s) is selected from the group consisting of non- biological DMARDs, NSAI DS, and corticosteroids.
These additional therapeutic agents may be administered via the same or a different administration route as (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin- 3-yl) methyl)amino)acetate according to the present invention. Furthermore, they may be
administered in the same dosage/dosage regimen as (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate according to the present invention.
I f additional therapeutic agents are utilised, in one embodiment, the combined action of (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate and the additional therapeutic agent(s) is greater than the sum or each acting separately. The combination of two or more therapeutic agents may, thus, provide a synergistic effect.
Combination therapy with one or more additional therapeutic agents includes coadministration (simultaneous administration) and sequential or consecutive administration . Agents intended for use in combination may be formulated in separate compositions or, if the same dosage regimen can be used for all agents, a single pharmaceutical composition .
I t will be clear to a person skilled in the art that, where appropriate, the other therapeutic agent(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or as solvates, for example hydrates, to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic agent. I t will be clear also that, where appropriate, the therapeutic agents may be used in optically pure form .
EXAM PLES
Exam ple 1 : Pharmaceut ical Com positions
The following are example capsule compositions for use in therapy as described herein. References in the Examples to "the compound" or "compound" refer to (S)-cyclopentyl 2-cyclohexyl- 2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate as the free base.
Table 1 : Example Capsule Composition ( 1 )
Capsules are white, opaque, hard gelatine capsules for oral administration. The capsules may be packed into high-density polyethylene (HDPE) bottles with child resistant closures and also may include a dessicant.
I n a first clinical study of the compound, cohorts of healthy male volunteers received doses of the compound either as single ascending doses up to 60 mg ( Part A: 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, and 60 mg doses) or as multiple ascending doses of up to 40 mg once daily for 7 days ( Part B: 20 mg and 40 mg doses) . This study was to determine the safety and tolerability of the compound and characterised the pharmacokinetics of the compound and its acid (the corresponding acid product is produced from hydrolysis of the ester by the intracellular esterase, carboxy-esterase- 1 (hCE-1 )) . The study also explored the pharmacodynamic profile of the compound.
The compound was found to be well tolerated ; however, a decision was made to not complete the final planned cohort at 60 mg in order to investigate the emergence of an unexpected pharmacodynamic observation : marked depletion of circulating monocytes.
Pharmacodynamics
Monocyte Counts
I n Part A, from Cohort 2 (10 mg) onwards there was a decrease in the monocyte count observed at 4 hours and which showed a greater decrease at 24 hours post dosing. I n the post-dose sample collected at post-study physical examination (performed between 4 to 7 days after the last
study treatment) the decrease in monocytes had reversed (see Figure 1 ) . I n Part B, in both cohorts (20 mg and 40 mg) , rapid depletion in monocytes was seen which then plateaued around Day 2. I n the post-dose sample collected at post-study physical examination (performed between 4 to 7 days after the last study treatment) the monocyte count had returned to baseline (see Figure 2) .
Acid Retention in Monocytes
The concentration of the acid hydrolysis product in monocytes and non-monocyte cell populations was determined as part of the study.
I n Part A, the peak mean concentration of the acid in monocytes and
non-monocytes tended to occur at approximately 1 hour post-dose across all treatment groups (see Figure 3) . The mean concentration of the acid in monocytes (negatively selected from PBMCs) and in non-monocytes (remaining PBMCs) tended to increase with dose at all timepoints. Overall, concentrations of the acid tended to be higher in monocytes than in non-monocytes and remained detectable 12 hours post dose, well beyond plasma concentrations. Concentration above I C90 was maintained for up to 1 .8 hours at 20 mg and up to 7.6 hours at 40 mg after one single dose.
I n Part B, the peak mean concentration of acid in monocytes and non-monocytes tended to occur at 1 hour post-dose across both active treatment groups on Day 1 and on Day 7 (see Figure 4) . The mean concentration of acid in monocytes and non-monocytes tended to increase with dose at 1 and 4 hours post-dose at Day 1 , but not at Day 7. Concentrations of the acid tended to be much higher in monocytes than in non-monocytes from 1 hour to 12 hours post-dose. Pre-dose levels of the acid on Day 7 in monocytes were similar to levels on Day 1 , 12 hours post-dose.
Change in Acetylation Levels of Monocytes, Lymphocytes and Granulocytes Over Time
I n Part A, the level of acetylation of monocytes was greater than non-monocytes
(granulocytes and lymphocytes) from 1 hour to 12 hours post-dose from 10 mg to 60 mg, inclusive (See Figure 5) .
I n Part B, the level of acetylation of monocytes was greater than non-monocytes
(granulocytes and lymphocytes) from 1 hour to 12 hours post-dose in Cohort 1 (20 mg) and Cohort 2 (40 mg) (See Figure 6) . Monocyte acetylation was maintained beyond plasma concentrations. There was increased acetylation on Day 7 pre-dose (24 hours post-6th dose) , which was further increased upon administration of a further dose of the compound.
Cytokine I nhibition
Cytokines levels were measured in fasted state. In general, for all cytokines (TNFa, IL-6, I L- 10, I FN-γ and IL- Ιβ) some degree of inhibition of LPS-induced production was observed.
I n Part A, mean percentage levels of LPS-induced TNFa and LPS-induced I L-6 were below 50% of baseline levels in Cohort 3 (20 mg, fasted) , Cohort 4 (40 mg, fasted) , Cohort 5 (60 mg) and Cohort 6 (50 mg) , and these levels remained below 50% up to 12 hours post-dose. Levels of LPS- induced I L-10 were also below 50% of baseline levels in Cohort 2 (10 mg) , Cohort 3 (20 mg, fasted) , Cohort 4 (40 mg, fasted) , Cohort 5 (60 mg) and Cohort 6 (50 mg) with levels remaining
below 50% of baseline levels in Cohorts 4, 5 and 6 up to 12 hours post-dose. Mean percentage levels of LPS-induced I L- Ιβ of Cohort 4 (40 mg, fasted) , Cohort 5 (60 mg) and Cohort 6 (50 mg) , remained below 50% of baseline levels up to 12 hours post-dose.
I n Part B, mean percentage levels of LPS-induced TNFa, IL-6, I L-10, I FN-γ and IL-Ιβ were less than 50% from baseline on Day 1 , and remained below 50% of baseline levels at 12 hours post-dose on Day 7 for both cohorts. For all cytokine levels across the 2 treatment groups, there was a difference between placebo and active treatments.
[Exam ple 3 : Leukocyte Profiling Study
To investigate the reductions in monocytes observed in the Phase 1 healthy volunteer clinical study discussed above, a series of mechanistic studies were carried out, all in male hCE-1/ Es1 e mice (since rodent monocytes do not contain a homologue of hCE-1 , these transgenic mice were generated with the human hCE-1 gene under the control of the human CD68 promoter to drive expression in monocytes and macrophages [Gough et al, I mmunology, 103(3) , 351 -361 , (2001 )] . Given the high levels of plasma esterase activity in mouse blood, these transgenic mice were also crossed with an esterase-deficient ( Es1 e) mice to generate hCE-1 / Es1 e strain.) . Since rodent monocytes do not contain a homologue of hCE-1 , these transgenic mice were
generated with the human hCE-1 gene under the control of the human CD68 promoter to drive expression in monocytes and macrophages [Gough, 2001 ] . Given the high levels of plasma esterase activity in mouse blood, these transgenic mice were also crossed with an esterase-deficient ( Es1 e) mice to generate hCE-1 / Es1 e strain. The compound at 10 mg/kg/day by intraperitoneal ( I P) injection was selected as a standard dose and 6 hours was selected as the standard timepoint across all studies.
Study 1
A study was designed to evaluate effect of a single dose of the compound on leukocyte populations in the blood of male hCE1 / Es1 e mice at 1 h , 6h and 24h post dose. I n two separate experiments cardiac bleeds were taken and flow cytometry analysis showed that circulating monocytes were significantly decreased by 78 and 67% after 6h. This was confirmed by additional blood smear analysis and automated cell counting. I n summary, these studies illustrate that treatment of hCE1 / Es1 e mice with the compound administered by intraperitoneal ( I P) injection at 1 0 mg/kg resulted in a selective and significant decrease in circulating monocytes at 6h .
Study 2
This study was designed to evaluate the effects of two intraperitoneal doses of 10 mg/kg compound, (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, on leukocyte populations in the blood of male hCE1 / Es1 e mice. Mice were dosed at 0 and 24h and circulating leukocyte levels were assessed by flow cytometry and blood smear analysis at 6h , 24h and 30h (i.e. 6h post second dose) . Flow cytometric analysis of blood showed a significant decrease in circulating monocytes at the 6h timepoint (82% ) followed by a
return to levels comparable to vehicle control animals by 24h. Following a second administration of the compound at 24h there was an 84% decrease in circulating monocytes at 30h, which is a similar magnitude to that seen at 6h, indicating reproducible effects of multiple dosing. The percentage of B cells, T cells and neutrophils were unaffected.
Study 3
This study was designed to compare the effects of a single intaperitoneal dose of two targeted HDAC inhibitors ((S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate and (S)-cyclopentyl 2-cyclohexyl-2-((4-(3-(hydroxyamino)-3- oxopropyl)benzyl)amino)acetate) and the non-targeted HDAC inhibitor SAHA (vorinostat) on leukocyte populations in the blood of male hCE1 / Es1 e mice at 6h post dose. Both targeted compounds were dosed at 10 mg/kg and SAHA was dosed at 100 mg/kg. Flow cytometric analysis of CD45+ leukocytes revealed a significant decrease in monocytes by both targeted HDAC inhibitors at 6h which was not seen with SAHA. However, SAHA caused an increase in circulating granulocytes. I n order to exclude the possibility that this influx might be impacting the analysis of monocytes (when expressed as % CD45+ leukocytes) the data were re-analysed excluding granulocytes. Upon reanalysis the specific effects of the targeted HDAC compounds on monocytes were confirmed. Both analysis methods revealed that all monocyte subsets were significantly reduced with the targeted HDAC compounds, with a more substantial decrease in the Ly6Cint and Ly6C'° subsets.
Study 4
This study investigated the effects of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-
3-oxopropyl)pyridin-3-yl)methyl) amino)acetate and a non-hydrolysable t-butyl ester control ((S)-tert- butyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate) on leukocytes at 6h post intraperitoneal dosing of male hCE1 / Es1 e mice. Leukocyte populations were assessed by flow cytometry phenotyping and the study was designed to determine the effects of the non-hydrolysable t-butyl control molecule dosed at 10 mg/kg on circulating leukocytes, and to evaluate the effects of 3 mg/kg and 10 mg/kg (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)- 3-oxopropyl)pyridin-3-yl)methyl) amino)acetate on circulating leukocytes compared to vehicle-treated animals.
When the t-butyl ester control was dosed at 10 mg/kg no effect on circulating monocytes was observed. Furthermore, a 10 mg/kg dose of the t-butyl ester control molecule did not alter B cell, T cell or neutrophil populations in the blood.
A significant decrease in circulating monocytes was seen in animals treated with 3 mg/kg (59% decrease) or 10 mg/kg (78% decrease) of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, when data were analysed as percentage of CD45+ cells. Absolute cell counts confirmed this observation. Although the decrease in monocytes was greater with the 10 mg/kg dose, this was not statistically different from 3 mg/kg. Similarly, all monocyte subsets were decreased by both 3 and 10 mg/kg (S)-cyclopentyl 2-cyclohexyl-
2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, with the Ly6Cint and Ly6C 10 monocyte subsets being more substantially decreased.
Exam ple 4 : Anti-Collagen Antibody I nduced Arthritis Studies
These studies have been included to support the use of the compound of the invention in the treatment of arthritis.
Four studies were performed to evaluate the efficacy of the compound in the murine Anti- Collagen Antibody I nduced Arthritis (ACAI A) model; two in which the drug was administered by intaperitoneal ( I P) injection and two using the oral route. The model was run in transgenic mice over-expressing human carboxyesterase-1 (hCE-1 ) .
I n the two I P administration studies, arthritis was induced in hCE1 transgenic and wild type mice by administering 4 mg of a monoclonal antibody (mAb) cocktail intravenously on study day 0. Three days post the single mAb administrations, all animals were subjected to a single
intraperitoneal injection of LPS (50 μς/ηηοιιεΘ). hCEl transgenic or wild type mice were treated with vehicle control or compound at 30 mg/kg, 10 mg/kg or 3mg/kg intraperitoneal^ on days 0-1 1 . All mice were monitored for the development of arthritis and clinical signs, and were weighed, on days 0 and 3-12.
The endpoints evaluated were incidence of arthritis, clinical score (front paws, rear paws and total) , paw thickness (front and rear) and body weight. I n the strain of mice used, the severity of the disease is less evident in the rear paws.
Treatment of hCE1 transgenic mice with the compound, (S)-cyclopentyl 2-cyclohexyl-2-(((6-
(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, administered by intaperitoneal ( I P) injection at 10 mg/kg or 3 mg/kg (Study A) significantly inhibited the development of arthritis with sustained reductions in total paw score, fore paw score and fore paw thickness. I n addition, a sustained reduction in rear paw score was observed, however, this was not significant. To a lesser extent, treatment with the compound at 1 mg/kg also resulted in reductions in total arthritis scores, fore paw scores and fore paw thickness, however, this was not significant.
Treatment of hCE1 transgenic mice with the compound administered by intaperitoneal ( I P) injection at 30 mg/kg or 10 mg/kg (Study B) significantly inhibited the development of arthritis with sustained reductions in total paw score, fore paw score and fore paw thickness. I n addition, a sustained reduction in rear paw score was observed, although this was not significant. Treatment with the compound at 3mg/kg also significantly inhibited the development of arthritis with reductions in total arthritis scores and fore paw scores. Treatment of wild type mice with the compound at 30 mg/kg or 10 mg/kg also reduced the development of arthritis, however, this was not significant.
I n two further studies, the compound was evaluated by oral administration at 0, 10, 30 and
100 mg/kg/day. At 100 mg/kg/day there was a reduction in the severity of arthritis, with statistically significant reductions in total, fore and rear paw scores, and fore paw thickness.
Example 5 : Monocyte Count Profiling
A K-PD model (Jacqmin et al, J Pharmacokineti Pharmacodyn, 2007, 34(1 ) , pages 57-85) was fitted to Part A and Part B monocyte count data at Example 2 using NONMEM® (http://www.iconplc.com/innovation/solutions/nonmem/) , I CON'S non-linear, mixed effects modeling tool for Population Pharmacokinetic/ Pharmacodynamic ( PK/PD) data analysis, version 7.2 and Perl- speaks-NONMEM (PsN) version 3.4.2 (http://psn.sourceforge.net ) . The fitted model was subsequently utilized to simulate the monocyte count profile after every day, every other day and every three days dosing of 20mg and 40mg of the compound. The simulations were performed using R software environment, version 3.0.1 (https://www.r-project.org/about.html) . Figures 7A/B: Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering three every other day doses of 20 and 40 mg of compound. Figures 7C: Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering three every day doses of 20 and 40 mg of compound. . Figures 7D: Medians (solid and dashed lines) and their 80% prediction intervals (grey ribbons) from 300 simulations considering inter-subject variability, when administering two doses of 20 and 40 mg of compound, each one every three days (Q3D strategy) .
Example 6 : Clinical Study in Patients
This study will evaluate the efficacy, safety and tolerability of the compound at a dose of 40 mg orally every other day in subjects with severe rheumatoid arthritis despite treatment with disease- modifying anti-rheumatic drugs (DMARDs) . This study as a secondary objective, will also investigate the monocyte numbers after every other day dosing with the compound.
This is a randomised, double-blind (sponsor open) , multicentre, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability, PK and PD of the compound in subjects with RA resistant to DMARD therapy.
The total maximum study duration is approximately 10 weeks (not including any rescreen) . Following a screening period of up to 28 days, subjects will be randomised ( 1 : 1 ) to placebo or 40 mg of the compound orally-administered every other day for a period of 28 days (14 doses) . Subjects will be followed up for 7-14 days post final dose.
Approximately 40 subjects with severe RA despite treatment with DMARDs will be randomised into the study. Subjects in this study are not currently benefiting from DMARD therapy therefore such DMARD therapies will be excluded for the duration of the study. Any subject currently deriving benefit from DMARD therapy will not be included in this study.
I nclusion Criteria: Type of subject and diagnosis including disease severity
The subject must have a diagnosis of RA according to the 2010 ACR/ EULAR classification criteria for RA. Functional class I , I I or I I I defined by the 1992 ACR Classification of Functional Status in RA. The subject must have a EULAR DAS 28-CRP of greater than 5.1 at screening. Disease duration
of > 6 months (time from onset of patient-reported symptoms of either pain or stiff ness or swelling in hands, feet or wrists). Swollen joint count of >6 (66-joint count) and tender joint count of >8 (68- joint count) at screening and at day 1 . The subject must have a CRP serum level of > 5 mg/L at screening. The subject has had an inadequate response or intolerance of DMARDs (due to lack of efficacy or toxicity, after at least 8 weeks treatment) .
Claims
1 . (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, in a human or animal subject, by administration in an amount of about 10 mg to about 40 mg at a frequency of twice a week, three times a week, or every other day.
2. (S) -cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use according to claim 1 , wherein administration is every other day in an amount of about 10 mg to about 40 mg.
3. (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use according to claim 1 or claim 2, by administration in an amount of about 40 mg.
4. (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 3 wherein administration is orally.
5. (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 4 wherein the subject is a human.
6. A pharmaceutical composition for use in the treatment of a chronic inflammatory and/or autoimmune disease, such as rheumatoid arthritis, wherein the pharmaceutical composition comprises from about 10 mg to about 40 mg of (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is for administration twice a week, three times a week, or every other day.
7. A pharmaceutical composition for use according to claim 6, which is for administration every other day.
8. A pharmaceutical composition for use according to claim 6 or claim 7, wherein the
pharmaceutical composition comprises 40 mg of (S) -cyclopentyl 2-cyclohexyl-2-(((6-(3-
(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition for use according to any one of claims 6 to 8, wherein the pharmaceutical composition comprises (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate.
10. A pharmaceutical composition for use according to any one of claims 6 to 9, wherein the pharmaceutical composition is for oral administration .
1 1 . A pharmaceutical composition for use according to any of claims 6 to 10, wherein the pharmaceutical composition is in unit dosage form .
12. A pharmaceutical composition for use according to claim 1 1 , wherein the unit dosage form is a tablet or capsule.
13. A pharmaceutical composition for use according to any of claims 6 to 12, wherein said use is in the treatment of a human subject.
14. A pharmaceutical composition comprising (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3- (hydroxyamino)-3-oxopropyl)pyridin-3-yl)methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg, and a
pharmaceutically acceptable excipient.
15. A pharmaceutical composition according to claim 14, wherein (S)-cyclopentyl 2-cyclohexyl-2- (((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a
pharmaceutically acceptable salt thereof, is present in an amount of about 40 mg.
16. A pharmaceutical composition according to claim 14 or claim 15, which comprises (S)- cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate.
17. A pharmaceutical composition according to any one of claims 14 to 16 for oral
administration.
18. A pharmaceutical composition according to any one of claims 14 to 17, wherein the
pharmaceutical composition is in unit dosage form .
19. A pharmaceutical composition according to claim 18, wherein the unit dosage form is a tablet or a capsule.
20. A method of treating a chronic inflammatory and/or autoimmune disease, such as
rheumatoid arthritis, which method comprises administering to a human or animal subject in need thereof (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, in an amount of about 10 mg to about 40 mg twice a week, three times a week, or every other day.
21 . A method of treating according to claim 20, wherein administration is every other day.
22. A method of treating according to claim 20 or claim 21 , wherein (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate, or a pharmaceutically acceptable salt thereof, is administered in the amount of about 40 mg.
23. A method of treating according to any one of claims 20 to 22, which comprises administering (S)-cyclopentyl 2-cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3- yl) methyl)amino)acetate.
24. A method of treating according to any one of claims 20 to 23, wherein administration is oral.
25. A method of treating according to any one of claims 20 to 24, wherein (S)-cyclopentyl 2- cyclohexyl-2-(((6-(3-(hydroxyamino)-3-oxopropyl)pyridin-3-yl) methyl)amino)acetate or a
pharmaceutically acceptable salt thereof, is administered in the form of a pharmaceutical composition and further comprises a pharmaceutically acceptable excipient.
26. A method of treating according to claim 25, wherein the pharmaceutical composition is in unit dose form .
27. A method of treating according to claim 26, wherein the unit dose form is a tablet or capsule.
28. A method of treating according to any one of claims 20 to 27, wherein treatment is of a human subject.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1610502.5 | 2016-06-16 | ||
GBGB1610502.5A GB201610502D0 (en) | 2016-06-16 | 2016-06-16 | Dosage regimen |
GB1617850.1 | 2016-10-21 | ||
GBGB1617850.1A GB201617850D0 (en) | 2016-10-21 | 2016-10-21 | Dosage regimen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017216297A1 true WO2017216297A1 (en) | 2017-12-21 |
Family
ID=59215752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/064682 WO2017216297A1 (en) | 2016-06-16 | 2017-06-15 | Dosage regimen |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017216297A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117649950A (en) * | 2024-01-29 | 2024-03-05 | 北京大学第三医院(北京大学第三临床医学院) | Oxytocin pharmacokinetics model, and construction method and application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006117548A1 (en) | 2005-05-05 | 2006-11-09 | Chroma Therapeutics Ltd | Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity |
WO2006117567A2 (en) | 2005-05-05 | 2006-11-09 | Chroma Therapeutics Ltd | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
WO2006117549A1 (en) | 2005-05-05 | 2006-11-09 | Chroma Therapeutics Ltd | Enzyme inhibitors |
WO2008040934A1 (en) | 2006-10-06 | 2008-04-10 | Chroma Therapeutics Ltd. | Hdac inhibitors |
WO2008053131A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
WO2009106848A2 (en) | 2008-02-29 | 2009-09-03 | Chroma Therapeutics Ltd. | Enzyme and receptor modulation |
WO2010097586A1 (en) | 2009-02-27 | 2010-09-02 | Chroma Therapeutics Ltd. | Enzyme inhibitors |
WO2011017448A1 (en) * | 2009-08-05 | 2011-02-10 | The Trustees Of The University Of Pennsylvania | Use of histone deacetylase inhibitors for treatment of autoimmune diseases |
WO2012025701A1 (en) | 2010-08-25 | 2012-03-01 | Chroma Therapeutics Ltd. | Alpha, alpha - di substituted glycine ester derivatives and their use as hdac inhibitors |
-
2017
- 2017-06-15 WO PCT/EP2017/064682 patent/WO2017216297A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006117548A1 (en) | 2005-05-05 | 2006-11-09 | Chroma Therapeutics Ltd | Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity |
WO2006117567A2 (en) | 2005-05-05 | 2006-11-09 | Chroma Therapeutics Ltd | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
WO2006117549A1 (en) | 2005-05-05 | 2006-11-09 | Chroma Therapeutics Ltd | Enzyme inhibitors |
WO2008040934A1 (en) | 2006-10-06 | 2008-04-10 | Chroma Therapeutics Ltd. | Hdac inhibitors |
WO2008053131A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
WO2009106848A2 (en) | 2008-02-29 | 2009-09-03 | Chroma Therapeutics Ltd. | Enzyme and receptor modulation |
WO2010097586A1 (en) | 2009-02-27 | 2010-09-02 | Chroma Therapeutics Ltd. | Enzyme inhibitors |
WO2011017448A1 (en) * | 2009-08-05 | 2011-02-10 | The Trustees Of The University Of Pennsylvania | Use of histone deacetylase inhibitors for treatment of autoimmune diseases |
WO2012025701A1 (en) | 2010-08-25 | 2012-03-01 | Chroma Therapeutics Ltd. | Alpha, alpha - di substituted glycine ester derivatives and their use as hdac inhibitors |
Non-Patent Citations (13)
Title |
---|
C. A. ROBERTS ET AL., FRONTIERS IN IMMUNOLOGY, vol. 6, 2015, pages 571 |
DUNAY, I. R ET AL.: "inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii.", IMMUNITY, vol. 29, 2008, pages 306 - 317 |
FALKENBERG KJ ET AL.: "The role of HDAC inhibitors in cancer, neurological diseases and immune disorders has been reviewed", NAT REV DRUG DISCOV, vol. 13, 2014, pages 673 - 691 |
GOUGH ET AL., IMMUNOLOGY, vol. 103, no. 3, 2001, pages 351 - 361 |
JACQMIN ET AL., J PHARMACOKINETI PHARMACODYN, vol. 34, no. 1, 2007, pages 57 - 85 |
K M GURSES ET AL.: "Monocyte Toll-Like Receptor Expression in Patients with Atrial Fibrillation", AM J CARDIOL, vol. 117, 2016, pages 1463 - 1467, XP029496595, DOI: doi:10.1016/j.amjcard.2016.02.014 |
LEON, B. ET AL: "Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania", IMMUNITY, vol. 26, 2007, pages 519 - 531 |
LIM, J. K: "Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in west nile virus encephalitis", J. IMMUNOL, vol. 186, 2011, pages 471 - 478 |
PAMER, E.G: "Immune responses to Listeria monocytogenes", NATURE REV. /MMUNOL, vol. 4, 2004, pages 812 - 823 |
PETERS, W ET AL.: "Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis", PROC. NAT/ ACAD. SCI. USA, vol. 98, 2001, pages 7958 - 7963 |
S T GREN ET AL.: "Role of Monocytes and Intestinal Macrophages in Crohn's Disease and Ulcerative Colitis", INFLAMM BOWEL DIS, vol. 22, 8 August 2016 (2016-08-08) |
SERBINA, N.V. ET AL: "Monocyte-mediated defense against microbial pathogens", ANNU. REV. IMMUNOL, vol. 26, 2008, pages 421 - 452 |
TRAYNOR, T. R. ET AL: "CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection", J. IMMUNOL., vol. 164, 2000, pages 2021 - 2027 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117649950A (en) * | 2024-01-29 | 2024-03-05 | 北京大学第三医院(北京大学第三临床医学院) | Oxytocin pharmacokinetics model, and construction method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210008053A1 (en) | Combination therapies for treating cancer | |
JP2021091690A (en) | Novel combination treatment for acute myeloid leukemia (aml) | |
US20170002060A1 (en) | Polynucleotides for the in vivo production of antibodies | |
JP2011526244A (en) | How to treat inflammation | |
CN106132439A (en) | Comprise antiangiogenic agent and OX40 combines the combination treatment of agonist | |
EP3119401A2 (en) | Cenicriviroc for the treatment of fibrosis | |
CN105198997A (en) | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof | |
WO2022052874A1 (en) | Use of chiauranib in combination with immune checkpoint inhibitor in antitumor therapy | |
JP2018519335A (en) | Combination of HDAC inhibitor and anti-PD-L1 antibody for the treatment of cancer | |
EP3600326B1 (en) | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors | |
US20210198361A1 (en) | Biomarkers for determining the effectiveness of immune checkpoint inhibitors | |
CN112672744A (en) | Methods and compositions for inhibiting dihydroorotate dehydrogenase | |
US20210401851A1 (en) | Par-4 agonists for the treatment of cancer | |
US20060083714A1 (en) | Combination of a pde iv inhibitor and a tnf-alpha antagonist | |
US20210032333A1 (en) | Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors | |
US20210315880A1 (en) | Methods of treating viral infections using inhibitors of nucleotide synthesis pathways | |
US20230218605A1 (en) | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine | |
WO2017216297A1 (en) | Dosage regimen | |
WO2021207598A1 (en) | Combination treatment with an agonist of p53 and a second therapeutic agent | |
US20050261246A1 (en) | Methods for treating inflammatory and autoimmune diseases | |
Wei et al. | In vivo CRISPR gene editing in patients with herpes stromal keratitis | |
EP2107906B1 (en) | Novel therapeutic use for treating leukaemia | |
CA2754281C (en) | Antiviral combination of zinc and trimethoprim | |
US20230381179A1 (en) | Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation | |
EP4085908A1 (en) | Pharmaceutical combination for treating tumors and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17732845 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17732845 Country of ref document: EP Kind code of ref document: A1 |